A Phase 1/2 interventional study of Sasanlimab Prefilled syringe and Encorafenib in Carcinoma, Non-Small-Cell Lung, sponsored by Pfizer. Terminated at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 99th largest by enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 13 in phase 1/2, and was the 105th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.
Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination.
Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated.
Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Landscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell lung cancer (NSCLC). The purpose of this study is to learn if the study medicine (sasanlimab, a type of immunotherapy) along with other study medicines is safe and effective in people with non-small cell lung cancer that has spread outside of the lungs. There are currently two sub-studies using different types of medicines. People in the first sub-study will receive sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 4 weeks. Additionally, they will take targeted cancer therapies encorafenib by mouth once a day and binimetinib by mouth twice a day at home.
People in the second sub-study will receive the study medicine sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 3 weeks and will also receive SEA-TGT (an immunotherapy) by infusion every three weeks.
Additionally, they will take axitinib (a targeted therapy) by mouth twice a day at home.
In addition to taking the study drugs, participants in the sub-studies will be asked to visit the clinic for health checks. These include health questions, physical examinations, blood and urine samples, and imaging scans. These assessments help the study doctor and team to monitor the participants' safety and well-being, and to see how their cancer is responding to the treatment. Participants will continue in the study until the cancer is no longer responding to the study medicine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for Sub-Study A Phase 1b \&2:
-BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report.
Additional Inclusion Criteria for Sub-Study A Phase 1b only:
-Any for locally advanced/metastatic NSCLC.
Additional Inclusion Criteria for Sub-Study A Phase 2 only:
-Previously untreated for locally advanced/metastatic NSCLC
Additional Inclusion Criteria for Sub-Study B Phase 1b only::
-Any line of therapy for locally advanced/metastatic NSCLC.
Additional Inclusion Criteria for Sub-Study B Phase 2 only:
Exclusion Criteria Umbrella Phase 1b \&2:
Additional Exclusion Criteria for Sub-Study A Phase 1b\&2:
Additional Exclusion Criteria for Sub-Study A Phase 2 only:
-Prior therapy with , anti-PD-L1, or anti-PD-L2 agents.
Additional Exclusion Criteria for Sub-Study B Phase 1b\&2:
-Documentation of any tumor-driving molecular alteration (eg, BRAF, EGFR, ALK)
Additional Exclusion Criteria for Sub-Study B Phase 2 only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sasanlimab will be administered subcutaneously. Encorafenib \& binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
Drug: Sasanlimab Prefilled syringe · Drug: Encorafenib · Drug: Binimetinib
Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
Drug: Sasanlimab · Drug: Axitinib · Drug: SEA-TGT
prefilled syringe
capsules
tablets
solution supplied in vials
tablets
solution in vials
Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)
DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
Time frame: Day 1 up to Day 28 of Cycle 1
Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)
Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Phase 1b of Sub-Study B: Percentage of Participants With DLT
DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
Time frame: Day 1 up to Day 21 of Cycle 1
Phase 2 Sub-Study B: Objective Response Rate
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities
Hematology and clinical chemistry parameters were planned to be assessed.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR)
Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Phase 1b of Sub-Study A: Objective Response Rate
Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Phase 2 of Sub-Study A: Objective Response Rate
Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Phase 2 of Sub-Study A: Duration of Response (DR)
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first
Phase 2 of Sub-Study A: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response
Phase 2 of Sub-Study A: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first
Phase 2 of Sub-Study A: Overall Survival (OS)
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date
Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose.
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
Phase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Phase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Phase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Phase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Phase 1b of Sub-Study A: Ctrough of Encorafenib
Time frame: Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days)
Phase 2 of Sub-Study A: Ctrough of Encorafenib
Time frame: Cycle 5 Day 1 (pre-dose)
Phase 1b of Sub-Study A: Ctrough of Binimetinib
Time frame: Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days)
Phase 2 of Sub-Study A: Ctrough of Binimetinib
Time frame: Cycle 5 Day 1 (pre-dose)
Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days)
Phase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment
Phase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline
OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score
EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact.
Time frame: Baseline up to end of treatment
Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score
The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms.
Time frame: Baseline up to end of treatment
Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 39.3 months; maximum follow-up approximately 39.66 months)
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0
Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Phase 1b of Sub-Study B: Objective Response Rate
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months)
Phase 1b of Sub-Study B: Duration of Response (DR)
DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
Phase 1b of Sub-Study B: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
Phase 1b of Sub-Study B: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Phase 2 of Sub-Study B: Duration of Response (DR)
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
Phase 2 of Sub-Study B: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
Phase 2 of Sub-Study B: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Phase 2 of Sub-Study B: Overall Survival (OS)
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months)
Phase 1b of Sub-Study B: Cmax of Sasanlimab
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Cmax of Axitinib
Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Cmax of SEA-TGT
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Cmax of Sasanlimab
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Cmax of Axitinib
Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Cmax of SEA-TGT
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Sub-study A (SSA) was planned to be conducted in 2 parts: Phase 1b and Phase 2. Due to a business decision, Phase 2 was not initiated, hence no participants were enrolled for Phase 2 of SSA. Sub-study B (SSB) was conducted in 2 parts: Phase 1b and Phase 2.
| Milestone | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| Started | 4 | 9 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Global deterioration of health status | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| Started | 2 | 5 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 3 | 6 | 3 | 2 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 3 | 6 | 3 | 2 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 3 | 2 | 2 | 1 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Global deterioration of health status | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 2 | 3 | 3 | 2 | 6 |
| Completed | 0 | 0 | 1 | 0 | 2 | 1 | 3 |
| Not completed | 0 | 0 | 1 | 3 | 1 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 1 | 3 | 1 | 0 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
| Percentage of participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT) | 0 | 33.3 |
Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
No measurements were reported for this outcome.
DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
| Percentage of participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Phase 1b of Sub-Study B: Percentage of Participants With DLT | 0 | 1 |
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
| Percentage of participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 Sub-Study B: Objective Response Rate | 33.3 (0.8 to 90.6) | 0 (0.0 to 84.2) | 14.3 (0.4 to 57.9) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
| Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Grade 1 | 1 | 0 |
| Grade 2 | 0 | 2 |
| Grade 3 | 3 | 4 |
| Grade 4 | 0 | 2 |
| Grade 5 | 0 | 1 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
No measurements were reported for this outcome.
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
| Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Anemia — Grade 0 to 0 | 3 | 2 |
| Anemia — Grade 0 to 1 | 0 | 2 |
| Anemia — Grade 0 to 2 | 0 | 1 |
| Anemia — Grade 0 to 3 | 0 | 0 |
| Anemia — Grade 0 to 4 | NA | NA |
| Anemia — Grade 1 to 0 | 0 | 0 |
| Anemia — Grade 1 to 1 | 0 | 4 |
| Anemia — Grade 1 to 2 | 1 | 0 |
| Anemia — Grade 1 to 3 | 0 | 0 |
| Anemia — Grade 1 to 4 | NA | NA |
| Anemia — Grade 2 to 0 | 0 | 0 |
| Anemia — Grade 2 to 1 | 0 | 0 |
| Anemia — Grade 2 to 2 | 0 | 0 |
| Anemia — Grade 2 to 3 | 0 | 0 |
| Anemia — Grade 2 to 4 | NA | NA |
| Anemia — Grade 3 to 0 | 0 | 0 |
| Anemia — Grade 3 to 1 | 0 | 0 |
| Anemia — Grade 3 to 2 | 0 | 0 |
| Anemia — Grade 3 to 3 | 0 | 0 |
| Anemia — Grade 3 to 4 | NA | NA |
| Anemia — Grade 4 to 0 | NA | NA |
| Anemia — Grade 4 to 1 | NA | NA |
| Anemia — Grade 4 to 2 | NA | NA |
| Anemia — Grade 4 to 3 | NA | NA |
| Anemia — Grade 4 to 4 | NA | NA |
| Hemoglobin increased — Grade 0 to 0 | 4 | 8 |
| Hemoglobin increased — Grade 0 to 1 | 0 | 1 |
| Hemoglobin increased — Grade 0 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 4 | NA | NA |
| Hemoglobin increased — Grade 1 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 4 | NA | NA |
| Hemoglobin increased — Grade 2 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 4 | NA | NA |
| Hemoglobin increased — Grade 3 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 4 | NA | NA |
| Hemoglobin increased — Grade 4 to 0 | NA | NA |
| Hemoglobin increased — Grade 4 to 1 | NA | NA |
| Hemoglobin increased — Grade 4 to 2 | NA | NA |
| Hemoglobin increased — Grade 4 to 3 | NA | NA |
| Hemoglobin increased — Grade 4 to 4 | NA | NA |
| Leukocytosis — Grade 0 to 0 | 4 | 9 |
| Leukocytosis — Grade 0 to 1 | NA | NA |
| Leukocytosis — Grade 0 to 2 | NA | NA |
| Leukocytosis — Grade 0 to 3 | 0 | 0 |
| Leukocytosis — Grade 0 to 4 | NA | NA |
| Leukocytosis — Grade 1 to 0 | NA | NA |
| Leukocytosis — Grade 1 to 1 | NA | NA |
| Leukocytosis — Grade 1 to 2 | NA | NA |
| Leukocytosis — Grade 1 to 3 | NA | NA |
| Leukocytosis — Grade 1 to 4 | NA | NA |
| Leukocytosis — Grade 2 to 0 | NA | NA |
| Leukocytosis — Grade 2 to 1 | NA | NA |
| Leukocytosis — Grade 2 to 2 | NA | NA |
| Leukocytosis — Grade 2 to 3 | NA | NA |
| Leukocytosis — Grade 2 to 4 | NA | NA |
| Leukocytosis — Grade 3 to 0 | 0 | 0 |
| Leukocytosis — Grade 3 to 1 | NA | NA |
| Leukocytosis — Grade 3 to 2 | NA | NA |
| Leukocytosis — Grade 3 to 3 | 0 | 0 |
| Leukocytosis — Grade 3 to 4 | NA | NA |
| Leukocytosis — Grade 4 to 0 | NA | NA |
| Leukocytosis — Grade 4 to 1 | NA | NA |
| Leukocytosis — Grade 4 to 2 | NA | NA |
| Leukocytosis — Grade 4 to 3 | NA | NA |
| Leukocytosis — Grade 4 to 4 | NA | NA |
| Lymphocyte count decreased — Grade 0 to 0 | 2 | 3 |
| Lymphocyte count decreased — Grade 0 to 1 | 1 | 1 |
| Lymphocyte count decreased — Grade 0 to 2 | 1 | 2 |
| Lymphocyte count decreased — Grade 0 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 0 to 4 | 0 | 1 |
| Lymphocyte count decreased — Grade 1 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 2 | 0 | 1 |
| Lymphocyte count decreased — Grade 1 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 4 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 2 | 0 | 1 |
| Lymphocyte count decreased — Grade 2 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 4 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 2 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 4 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 2 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 4 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 0 | 4 | 9 |
| Lymphocyte count increased — Grade 0 to 1 | NA | NA |
| Lymphocyte count increased — Grade 0 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 4 | NA | NA |
| Lymphocyte count increased — Grade 1 to 0 | NA | NA |
| Lymphocyte count increased — Grade 1 to 1 | NA | NA |
| Lymphocyte count increased — Grade 1 to 2 | NA | NA |
| Lymphocyte count increased — Grade 1 to 3 | NA | NA |
| Lymphocyte count increased — Grade 1 to 4 | NA | NA |
| Lymphocyte count increased — Grade 2 to 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 1 | NA | NA |
| Lymphocyte count increased — Grade 2 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 4 | NA | NA |
| Lymphocyte count increased — Grade 3 to 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 1 | NA | NA |
| Lymphocyte count increased — Grade 3 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 4 | NA | NA |
| Lymphocyte count increased — Grade 4 to 0 | NA | NA |
| Lymphocyte count increased — Grade 4 to 1 | NA | NA |
| Lymphocyte count increased — Grade 4 to 2 | NA | NA |
| Lymphocyte count increased — Grade 4 to 3 | NA | NA |
| Lymphocyte count increased — Grade 4 to 4 | NA | NA |
| Neutrophil count decreased — Grade 0 to 0 | 4 | 7 |
| Neutrophil count decreased — Grade 0 to 1 | 0 | 1 |
| Neutrophil count decreased — Grade 0 to 2 | 0 | 1 |
| Neutrophil count decreased — Grade 0 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 0 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 4 | 0 | 0 |
| Platelet count decreased — Grade 0 to 0 | 4 | 7 |
| Platelet count decreased — Grade 0 to 1 | 0 | 1 |
| Platelet count decreased — Grade 0 to 2 | 0 | 0 |
| Platelet count decreased — Grade 0 to 3 | 0 | 0 |
| Platelet count decreased — Grade 0 to 4 | 0 | 0 |
| Platelet count decreased — Grade 1 to 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 1 | 0 | 0 |
| Platelet count decreased — Grade 1 to 2 | 0 | 1 |
| Platelet count decreased — Grade 1 to 3 | 0 | 0 |
| Platelet count decreased — Grade 1 to 4 | 0 | 0 |
| Platelet count decreased — Grade 2 to 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 1 | 0 | 0 |
| Platelet count decreased — Grade 2 to 2 | 0 | 0 |
| Platelet count decreased — Grade 2 to 3 | 0 | 0 |
| Platelet count decreased — Grade 2 to 4 | 0 | 0 |
| Platelet count decreased — Grade 3 to 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 1 | 0 | 0 |
| Platelet count decreased — Grade 3 to 2 | 0 | 0 |
| Platelet count decreased — Grade 3 to 3 | 0 | 0 |
| Platelet count decreased — Grade 3 to 4 | 0 | 0 |
| Platelet count decreased — Grade 4 to 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 1 | 0 | 0 |
| Platelet count decreased — Grade 4 to 2 | 0 | 0 |
| Platelet count decreased — Grade 4 to 3 | 0 | 0 |
| Platelet count decreased — Grade 4 to 4 | 0 | 0 |
| White blood cell decreased — Grade 0 to 0 | 3 | 8 |
| White blood cell decreased — Grade 0 to 1 | 1 | 0 |
| White blood cell decreased — Grade 0 to 2 | 0 | 0 |
| White blood cell decreased — Grade 0 to 3 | 0 | 0 |
| White blood cell decreased — Grade 0 to 4 | 0 | 0 |
| White blood cell decreased — Grade 1 to 0 | 0 | 0 |
| White blood cell decreased — Grade 1 to 1 | 0 | 0 |
| White blood cell decreased — Grade 1 to 2 | 0 | 0 |
| White blood cell decreased — Grade 1 to 3 | 0 | 00 |
| White blood cell decreased — Grade 1 to 4 | 0 | 0 |
| White blood cell decreased — Grade 2 to 0 | 0 | 0 |
| White blood cell decreased — Grade 2 to 1 | 0 | 0 |
| White blood cell decreased — Grade 2 to 2 | 0 | 1 |
| White blood cell decreased — Grade 2 to 3 | 0 | 0 |
| White blood cell decreased — Grade 2 to 4 | 0 | 0 |
| White blood cell decreased — Grade 3 to 0 | 0 | 0 |
| White blood cell decreased — Grade 3 to 1 | 0 | 0 |
| White blood cell decreased — Grade 3 to 2 | 0 | 0 |
| White blood cell decreased — Grade 3 to 3 | 0 | 0 |
| White blood cell decreased — Grade 3 to 4 | 0 | 0 |
| White blood cell decreased — Grade 4 to 0 | 0 | 0 |
| White blood cell decreased — Grade 4 to 1 | 0 | 0 |
| White blood cell decreased — Grade 4 to 2 | 0 | 0 |
| White blood cell decreased — Grade 4 to 3 | 0 | 0 |
| White blood cell decreased — Grade 4 to 4 | 0 | 0 |
Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
| Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Alanine aminotransferase increased — Grade 0 to 0 | 2 | 2 |
| Alanine aminotransferase increased — Grade 0 to 1 | 2 | 2 |
| Alanine aminotransferase increased — Grade 0 to 2 | 0 | 2 |
| Alanine aminotransferase increased — Grade 0 to 3 | 0 | 3 |
| Alanine aminotransferase increased — Grade 0 to 4 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 to 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 to 1 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 to 2 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 to 3 | 0 | 0 |
| Alanine aminotransferase increased — Grade 1 to 4 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 to 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 to 1 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 to 2 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 to 3 | 0 | 0 |
| Alanine aminotransferase increased — Grade 2 to 4 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 to 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 to 1 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 to 2 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 to 3 | 0 | 0 |
| Alanine aminotransferase increased — Grade 3 to 4 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 to 0 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 to 1 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 to 2 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 to 3 | 0 | 0 |
| Alanine aminotransferase increased — Grade 4 to 4 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 to 0 | 1 | 3 |
| Alkaline phosphatase increased — Grade 0 to 1 | 0 | 2 |
| Alkaline phosphatase increased — Grade 0 to 2 | 0 | 1 |
| Alkaline phosphatase increased — Grade 0 to 3 | 0 | 0 |
| Alkaline phosphatase increased — Grade 0 to 4 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 to 0 | 2 | 2 |
| Alkaline phosphatase increased — Grade 1 to 1 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 to 2 | 1 | 0 |
| Alkaline phosphatase increased — Grade 1 to 3 | 0 | 0 |
| Alkaline phosphatase increased — Grade 1 to 4 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 to 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 to 1 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 to 2 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 to 3 | 0 | 0 |
| Alkaline phosphatase increased — Grade 2 to 4 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 to 0 | 0 | 1 |
| Alkaline phosphatase increased — Grade 3 to 1 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 to 2 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 to 3 | 0 | 0 |
| Alkaline phosphatase increased — Grade 3 to 4 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 to 0 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 to 1 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 to 2 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 to 3 | 0 | 0 |
| Alkaline phosphatase increased — Grade 4 to 4 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 0 to 0 | 2 | 2 |
| Aspartate aminotransferase increased — Grade 0 to 1 | 2 | 4 |
| Aspartate aminotransferase increased — Grade 0 to 2 | 0 | 1 |
| Aspartate aminotransferase increased — Grade 0 to 3 | 0 | 1 |
| Aspartate aminotransferase increased — Grade 0 to 4 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 to 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 to 1 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 to 2 | 0 | 1 |
| Aspartate aminotransferase increased — Grade 1 to 3 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 1 to 4 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 to 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 to 1 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 to 2 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 to 3 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 2 to 4 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 to 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 to 1 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 to 2 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 to 3 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 3 to 4 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 to 0 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 to 1 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 to 2 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 to 3 | 0 | 0 |
| Aspartate aminotransferase increased — Grade 4 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 0 | 4 | 8 |
| Blood bilirubin increased — Grade 0 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 3 | 0 | 1 |
| Blood bilirubin increased — Grade 0 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 4 | 0 | 0 |
| CPK increased — Grade 0 to 0 | 2 | 4 |
| CPK increased — Grade 0 to 1 | 2 | 1 |
| CPK increased — Grade 0 to 2 | 0 | 2 |
| CPK increased — Grade 0 to 3 | 0 | 1 |
| CPK increased — Grade 0 to 4 | 0 | 1 |
| CPK increased — Grade 1 to 0 | 0 | 0 |
| CPK increased — Grade 1 to 1 | 0 | 0 |
| CPK increased — Grade 1 to 2 | 0 | 0 |
| CPK increased — Grade 1 to 3 | 0 | 0 |
| CPK increased — Grade 1 to 4 | 0 | 0 |
| CPK increased — Grade 2 to 0 | 0 | 0 |
| CPK increased — Grade 2 to 1 | 0 | 0 |
| CPK increased — Grade 2 to 2 | 0 | 0 |
| CPK increased — Grade 2 to 3 | 0 | 0 |
| CPK increased — Grade 2 to 4 | 0 | 0 |
| CPK increased — Grade 3 to 0 | 0 | 0 |
| CPK increased — Grade 3 to 1 | 0 | 0 |
| CPK increased — Grade 3 to 2 | 0 | 0 |
| CPK increased — Grade 3 to 3 | 0 | 0 |
| CPK increased — Grade 3 to 4 | 0 | 0 |
| CPK increased — Grade 4 to 0 | 0 | 0 |
| CPK increased — Grade 4 to 1 | 0 | 0 |
| CPK increased — Grade 4 to 2 | 0 | 0 |
| CPK increased — Grade 4 to 3 | 0 | 0 |
| CPK increased — Grade 4 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 0 | 1 | 3 |
| Chronic kidney disease — Grade 0 to 1 | 0 | 1 |
| Chronic kidney disease — Grade 0 to 2 | 2 | 3 |
| Chronic kidney disease — Grade 0 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 1 | 1 | 1 |
| Chronic kidney disease — Grade 1 to 2 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 2 | 0 | 1 |
| Chronic kidney disease — Grade 2 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 2 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 2 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 4 | 0 | 0 |
| Creatinine increased — Grade 0 to 0 | 1 | 6 |
| Creatinine increased — Grade 0 to 1 | 2 | 2 |
| Creatinine increased — Grade 0 to 2 | 1 | 1 |
| Creatinine increased — Grade 0 to 3 | 0 | 0 |
| Creatinine increased — Grade 0 to 4 | 0 | 0 |
| Creatinine increased — Grade 1 to 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 1 | 0 | 0 |
| Creatinine increased — Grade 1 to 2 | 0 | 0 |
| Creatinine increased — Grade 1 to 3 | 0 | 0 |
| Creatinine increased — Grade 1 to 4 | 0 | 0 |
| Creatinine increased — Grade 2 to 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 1 | 0 | 0 |
| Creatinine increased — Grade 2 to 2 | 0 | 0 |
| Creatinine increased — Grade 2 to 3 | 0 | 0 |
| Creatinine increased — Grade 2 to 4 | 0 | 0 |
| Creatinine increased — Grade 3 to 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 1 | 0 | 0 |
| Creatinine increased — Grade 3 to 2 | 0 | 0 |
| Creatinine increased — Grade 3 to 3 | 0 | 0 |
| Creatinine increased — Grade 3 to 4 | 0 | 0 |
| Creatinine increased — Grade 4 to 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 1 | 0 | 0 |
| Creatinine increased — Grade 4 to 2 | 0 | 0 |
| Creatinine increased — Grade 4 to 3 | 0 | 0 |
| Creatinine increased — Grade 4 to 4 | 0 | 0 |
| Hypercalcemia — Grade 0 to 0 | 3 | 4 |
| Hypercalcemia — Grade 0 to 1 | 1 | 5 |
| Hypercalcemia — Grade 0 to 2 | 0 | 0 |
| Hypercalcemia — Grade 0 to 3 | 0 | 0 |
| Hypercalcemia — Grade 0 to 4 | 0 | 0 |
| Hypercalcemia — Grade 1 to 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 1 | 0 | 0 |
| Hypercalcemia — Grade 1 to 2 | 0 | 0 |
| Hypercalcemia — Grade 1 to 3 | 0 | 0 |
| Hypercalcemia — Grade 1 to 4 | 0 | 0 |
| Hypercalcemia — Grade 2 to 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 1 | 0 | 0 |
| Hypercalcemia — Grade 2 to 2 | 0 | 0 |
| Hypercalcemia — Grade 2 to 3 | 0 | 0 |
| Hypercalcemia — Grade 2 to 4 | 0 | 0 |
| Hypercalcemia — Grade 3 to 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 1 | 0 | 0 |
| Hypercalcemia — Grade 3 to 2 | 0 | 0 |
| Hypercalcemia — Grade 3 to 3 | 0 | 0 |
| Hypercalcemia — Grade 3 to 4 | 0 | 0 |
| Hypercalcemia — Grade 4 to 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 1 | 0 | 0 |
| Hypercalcemia — Grade 4 to 2 | 0 | 0 |
| Hypercalcemia — Grade 4 to 3 | 0 | 0 |
| Hypercalcemia — Grade 4 to 4 | 0 | 0 |
| Hyperkalemia — Grade 0 to 0 | 4 | 8 |
| Hyperkalemia — Grade 0 to 1 | 0 | 1 |
| Hyperkalemia — Grade 0 to 2 | 0 | 0 |
| Hyperkalemia — Grade 0 to 3 | 0 | 0 |
| Hyperkalemia — Grade 0 to 4 | 0 | 0 |
| Hyperkalemia — Grade 1 to 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 1 | 0 | 0 |
| Hyperkalemia — Grade 1 to 2 | 0 | 0 |
| Hyperkalemia — Grade 1 to 3 | 0 | 0 |
| Hyperkalemia — Grade 1 to 4 | 0 | 0 |
| Hyperkalemia — Grade 2 to 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 1 | 0 | 0 |
| Hyperkalemia — Grade 2 to 2 | 0 | 0 |
| Hyperkalemia — Grade 2 to 3 | 0 | 0 |
| Hyperkalemia — Grade 2 to 4 | 0 | 0 |
| Hyperkalemia — Grade 3 to 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 1 | 0 | 0 |
| Hyperkalemia — Grade 3 to 2 | 0 | 0 |
| Hyperkalemia — Grade 3 to 3 | 0 | 0 |
| Hyperkalemia — Grade 3 to 4 | 0 | 0 |
| Hyperkalemia — Grade 4 to 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 1 | 0 | 0 |
| Hyperkalemia — Grade 4 to 2 | 0 | 0 |
| Hyperkalemia — Grade 4 to 3 | 0 | 0 |
| Hyperkalemia — Grade 4 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 0 | 4 | 8 |
| Hypermagnesemia — Grade 0 to 1 | 0 | 1 |
| Hypermagnesemia — Grade 0 to 2 | NA | NA |
| Hypermagnesemia — Grade 0 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 2 | NA | NA |
| Hypermagnesemia — Grade 1 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 2 to 0 | NA | NA |
| Hypermagnesemia — Grade 2 to 1 | NA | NA |
| Hypermagnesemia — Grade 2 to 2 | NA | NA |
| Hypermagnesemia — Grade 2 to 3 | NA | NA |
| Hypermagnesemia — Grade 2 to 4 | NA | NA |
| Hypermagnesemia — Grade 3 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 2 | NA | NA |
| Hypermagnesemia — Grade 3 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 2 | NA | NA |
| Hypermagnesemia — Grade 4 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 4 | 0 | 0 |
| Hypernatremia — Grade 0 to 0 | 4 | 8 |
| Hypernatremia — Grade 0 to 1 | 0 | 1 |
| Hypernatremia — Grade 0 to 2 | 0 | 0 |
| Hypernatremia — Grade 0 to 3 | 0 | 0 |
| Hypernatremia — Grade 0 to 4 | 0 | 0 |
| Hypernatremia — Grade 1 to 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 1 | 0 | 0 |
| Hypernatremia — Grade 1 to 2 | 0 | 0 |
| Hypernatremia — Grade 1 to 3 | 0 | 0 |
| Hypernatremia — Grade 1 to 4 | 0 | 0 |
| Hypernatremia — Grade 2 to 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 1 | 0 | 0 |
| Hypernatremia — Grade 2 to 2 | 0 | 0 |
| Hypernatremia — Grade 2 to 3 | 0 | 0 |
| Hypernatremia — Grade 2 to 4 | 0 | 0 |
| Hypernatremia — Grade 3 to 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 1 | 0 | 0 |
| Hypernatremia — Grade 3 to 2 | 0 | 0 |
| Hypernatremia — Grade 3 to 3 | 0 | 0 |
| Hypernatremia — Grade 3 to 4 | 0 | 0 |
| Hypernatremia — Grade 4 to 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 1 | 0 | 0 |
| Hypernatremia — Grade 4 to 2 | 0 | 0 |
| Hypernatremia — Grade 4 to 3 | 0 | 0 |
| Hypernatremia — Grade 4 to 4 | 0 | 0 |
| Hypoalbuminemia — Grade 0 to 0 | 2 | 3 |
| Hypoalbuminemia — Grade 0 to 1 | 1 | 3 |
| Hypoalbuminemia — Grade 0 to 2 | 0 | 1 |
| Hypoalbuminemia — Grade 0 to 3 | 1 | 0 |
| Hypoalbuminemia — Grade 0 to 4 | NA | NA |
| Hypoalbuminemia — Grade 1 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 1 | 0 | 1 |
| Hypoalbuminemia — Grade 1 to 2 | 0 | 1 |
| Hypoalbuminemia — Grade 1 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 4 | NA | NA |
| Hypoalbuminemia — Grade 2 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 1 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 2 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 4 | NA | NA |
| Hypoalbuminemia — Grade 3 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 1 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 2 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 4 | NA | NA |
| Hypoalbuminemia — Grade 4 to 0 | NA | NA |
| Hypoalbuminemia — Grade 4 to 1 | NA | NA |
| Hypoalbuminemia — Grade 4 to 2 | NA | NA |
| Hypoalbuminemia — Grade 4 to 3 | NA | NA |
| Hypoalbuminemia — Grade 4 to 4 | NA | NA |
| Hypocalcemia — Grade 0 to 0 | 4 | 7 |
| Hypocalcemia — Grade 0 to 1 | 0 | 2 |
| Hypocalcemia — Grade 0 to 2 | 0 | 0 |
| Hypocalcemia — Grade 0 to 3 | 0 | 0 |
| Hypocalcemia — Grade 0 to 4 | 0 | 0 |
| Hypocalcemia — Grade 1 to 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 1 | 0 | 0 |
| Hypocalcemia — Grade 1 to 2 | 0 | 0 |
| Hypocalcemia — Grade 1 to 3 | 0 | 0 |
| Hypocalcemia — Grade 1 to 4 | 0 | 0 |
| Hypocalcemia — Grade 2 to 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 1 | 0 | 0 |
| Hypocalcemia — Grade 2 to 2 | 0 | 0 |
| Hypocalcemia — Grade 2 to 3 | 0 | 0 |
| Hypocalcemia — Grade 2 to 4 | 0 | 0 |
| Hypocalcemia — Grade 3 to 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 1 | 0 | 0 |
| Hypocalcemia — Grade 3 to 2 | 0 | 0 |
| Hypocalcemia — Grade 3 to 3 | 0 | 0 |
| Hypocalcemia — Grade 3 to 4 | 0 | 0 |
| Hypocalcemia — Grade 4 to 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 1 | 0 | 0 |
| Hypocalcemia — Grade 4 to 2 | 0 | 0 |
| Hypocalcemia — Grade 4 to 3 | 0 | 0 |
| Hypocalcemia — Grade 4 to 4 | 0 | 0 |
| Hypoglycemia — Grade 0 to 0 | 4 | 7 |
| Hypoglycemia — Grade 0 to 1 | 0 | 1 |
| Hypoglycemia — Grade 0 to 2 | 0 | 0 |
| Hypoglycemia — Grade 0 to 3 | 0 | 0 |
| Hypoglycemia — Grade 0 to 4 | 0 | 0 |
| Hypoglycemia — Grade 1 to 0 | 0 | 1 |
| Hypoglycemia — Grade 1 to 1 | 0 | 0 |
| Hypoglycemia — Grade 1 to 2 | 0 | 0 |
| Hypoglycemia — Grade 1 to 3 | 0 | 0 |
| Hypoglycemia — Grade 1 to 4 | 0 | 0 |
| Hypoglycemia — Grade 2 to 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 1 | 0 | 0 |
| Hypoglycemia — Grade 2 to 2 | 0 | 0 |
| Hypoglycemia — Grade 2 to 3 | 0 | 0 |
| Hypoglycemia — Grade 2 to 4 | 0 | 0 |
| Hypoglycemia — Grade 3 to 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 1 | 0 | 0 |
| Hypoglycemia — Grade 3 to 2 | 0 | 0 |
| Hypoglycemia — Grade 3 to 3 | 0 | 0 |
| Hypoglycemia — Grade 3 to 4 | 0 | 0 |
| Hypoglycemia — Grade 4 to 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 1 | 0 | 0 |
| Hypoglycemia — Grade 4 to 2 | 0 | 0 |
| Hypoglycemia — Grade 4 to 3 | 0 | 0 |
| Hypoglycemia — Grade 4 to 4 | 0 | 0 |
| Hypokalemia — Grade 0 to 0 | 4 | 7 |
| Hypokalemia — Grade 0 to 1 | NA | NA |
| Hypokalemia — Grade 0 to 2 | 0 | 1 |
| Hypokalemia — Grade 0 to 3 | 0 | 1 |
| Hypokalemia — Grade 0 to 4 | 0 | 0 |
| Hypokalemia — Grade 1 to 0 | NA | NA |
| Hypokalemia — Grade 1 to 1 | NA | NA |
| Hypokalemia — Grade 1 to 2 | NA | NA |
| Hypokalemia — Grade 1 to 3 | NA | NA |
| Hypokalemia — Grade 1 to 4 | NA | NA |
| Hypokalemia — Grade 2 to 0 | 0 | 0 |
| Hypokalemia — Grade 2 to 1 | NA | NA |
| Hypokalemia — Grade 2 to 2 | 0 | 0 |
| Hypokalemia — Grade 2 to 3 | 0 | 0 |
| Hypokalemia — Grade 2 to 4 | 0 | 0 |
| Hypokalemia — Grade 3 to 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 1 | NA | NA |
| Hypokalemia — Grade 3 to 2 | 0 | 0 |
| Hypokalemia — Grade 3 to 3 | 0 | 0 |
| Hypokalemia — Grade 3 to 4 | 0 | 0 |
| Hypokalemia — Grade 4 to 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 1 | NA | NA |
| Hypokalemia — Grade 4 to 2 | 0 | 0 |
| Hypokalemia — Grade 4 to 3 | 0 | 0 |
| Hypokalemia — Grade 4 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 0 | 4 | 8 |
| Hypomagnesemia — Grade 0 to 1 | 0 | 1 |
| Hypomagnesemia — Grade 0 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 4 | 0 | 0 |
| Hyponatremia — Grade 0 to 0 | 3 | 5 |
| Hyponatremia — Grade 0 to 1 | 0 | 1 |
| Hyponatremia — Grade 0 to 2 | NA | NA |
| Hyponatremia — Grade 0 to 3 | 0 | 1 |
| Hyponatremia — Grade 0 to 4 | 0 | 0 |
| Hyponatremia — Grade 1 to 0 | 1 | 0 |
| Hyponatremia — Grade 1 to 1 | 0 | 0 |
| Hyponatremia — Grade 1 to 2 | NA | NA |
| Hyponatremia — Grade 1 to 3 | 0 | 2 |
| Hyponatremia — Grade 1 to 4 | 0 | 0 |
| Hyponatremia — Grade 2 to 0 | NA | NA |
| Hyponatremia — Grade 2 to 1 | NA | NA |
| Hyponatremia — Grade 2 to 2 | NA | NA |
| Hyponatremia — Grade 2 to 3 | NA | NA |
| Hyponatremia — Grade 2 to 4 | NA | NA |
| Hyponatremia — Grade 3 to 0 | 0 | 0 |
| Hyponatremia — Grade 3 to 1 | 0 | 0 |
| Hyponatremia — Grade 3 to 2 | NA | NA |
| Hyponatremia — Grade 3 to 3 | 0 | 0 |
| Hyponatremia — Grade 3 to 4 | 0 | 0 |
| Hyponatremia — Grade 4 to 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 1 | 0 | 0 |
| Hyponatremia — Grade 4 to 2 | NA | NA |
| Hyponatremia — Grade 4 to 3 | 0 | 0 |
| Hyponatremia — Grade 4 to 4 | 0 | 0 |
| Lipase increased — Grade 0 to 0 | 1 | 5 |
| Lipase increased — Grade 0 to 1 | 2 | 3 |
| Lipase increased — Grade 0 to 2 | 1 | 1 |
| Lipase increased — Grade 0 to 3 | 0 | 0 |
| Lipase increased — Grade 0 to 4 | 0 | 0 |
| Lipase increased — Grade 1 to 0 | 0 | 0 |
| Lipase increased — Grade 1 to 1 | 0 | 0 |
| Lipase increased — Grade 1 to 2 | 0 | 0 |
| Lipase increased — Grade 1 to 3 | 0 | 0 |
| Lipase increased — Grade 1 to 4 | 0 | 0 |
| Lipase increased — Grade 2 to 0 | 0 | 0 |
| Lipase increased — Grade 2 to 1 | 0 | 0 |
| Lipase increased — Grade 2 to 2 | 0 | 0 |
| Lipase increased — Grade 2 to 3 | 0 | 0 |
| Lipase increased — Grade 2 to 4 | 0 | 0 |
| Lipase increased — Grade 3 to 0 | 0 | 0 |
| Lipase increased — Grade 3 to 1 | 0 | 0 |
| Lipase increased — Grade 3 to 2 | 0 | 0 |
| Lipase increased — Grade 3 to 3 | 0 | 0 |
| Lipase increased — Grade 3 to 4 | 0 | 0 |
| Lipase increased — Grade 4 to 0 | 0 | 0 |
| Lipase increased — Grade 4 to 1 | 0 | 0 |
| Lipase increased — Grade 4 to 2 | 0 | 0 |
| Lipase increased — Grade 4 to 3 | 0 | 0 |
| Lipase increased — Grade 4 to 4 | 0 | 0 |
| Serum amylase increased — Grade 0 to 0 | 4 | 7 |
| Serum amylase increased — Grade 0 to 1 | 0 | 0 |
| Serum amylase increased — Grade 0 to 2 | 0 | 0 |
| Serum amylase increased — Grade 0 to 3 | 0 | 1 |
| Serum amylase increased — Grade 0 to 4 | 0 | 0 |
| Serum amylase increased — Grade 1 to 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 1 | 0 | 1 |
| Serum amylase increased — Grade 1 to 2 | 0 | 0 |
| Serum amylase increased — Grade 1 to 3 | 0 | 0 |
| Serum amylase increased — Grade 1 to 4 | 0 | 0 |
| Serum amylase increased — Grade 2 to 0 | 0 | 0 |
| Serum amylase increased — Grade 2 to 1 | 0 | 0 |
| Serum amylase increased — Grade 2 to 2 | 0 | 0 |
| Serum amylase increased — Grade 2 to 3 | 0 | 0 |
| Serum amylase increased — Grade 2 to 4 | 0 | 0 |
| Serum amylase increased — Grade 3 to 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 1 | 0 | 0 |
| Serum amylase increased — Grade 3 to 2 | 0 | 0 |
| Serum amylase increased — Grade 3 to 3 | 0 | 0 |
| Serum amylase increased — Grade 3 to 4 | 0 | 0 |
| Serum amylase increased — Grade 4 to 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 1 | 0 | 0 |
| Serum amylase increased — Grade 4 to 2 | 0 | 0 |
| Serum amylase increased — Grade 4 to 3 | 0 | 0 |
| Serum amylase increased — Grade 4 to 4 | 0 | 0 |
Hematology and clinical chemistry parameters were planned to be assessed.
No measurements were reported for this outcome.
Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
| Percentage of Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR) | 25.0 (0.6 to 80.6) | 44.4 (13.7 to 78.8) |
Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
| Percentage of Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Phase 1b of Sub-Study A: Objective Response Rate | 50.0 (6.8 to 93.2) | 44.4 (13.7 to 78.8) |
Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
No measurements were reported for this outcome.
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
No measurements were reported for this outcome.
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
No measurements were reported for this outcome.
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
No measurements were reported for this outcome.
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
No measurements were reported for this outcome.
AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose.
| Micrograms*hour per milliliter | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab | 12500 ± 65 | 24850 ± 17 |
No measurements were reported for this outcome.
| Micrograms per milliliter | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Cycle 1 | 29.49 ± 55 | 45.04 ± 38 |
| Cycle 5 | 64.60 ± NA | 70.90 ± NA |
No measurements were reported for this outcome.
| Hour | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Cycle 1 | 164 (144 to 168) | 209 (143 to 359) |
| Cycle 5 | 168 (168 to 168) | 162 (162 to 162) |
No measurements were reported for this outcome.
| Microgram per milliliter | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | 37.97 ± 20 | 40.24 ± NA |
No measurements were reported for this outcome.
| Nanograms per milliliter | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Cycle 1 Day 1 | NA ± NA | NA ± NA |
| Cycle 1 Day 15 | 12.2 ± 176 | 18.5 ± 50 |
| Cycle 2 Day 1 | — | 11.1 ± 204 |
| Cycle 5 Day 1 | 5.0 ± NA | 7.8 ± 191 |
No measurements were reported for this outcome.
| Nanograms per milliliter | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| Cycle 2 Day 1 | 19.2 ± NA | 40.9 ± 98 |
| Cycle 5 Day 1 | — | 35.7 ± 67 |
No measurements were reported for this outcome.
In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
| Participants | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) |
|---|---|---|
| ADA | 0 | 1 |
| NAb | 0 | 0 |
No measurements were reported for this outcome.
OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed.
No measurements were reported for this outcome.
EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact.
No measurements were reported for this outcome.
The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
| Participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Grade 1 | 0 | 0 |
| Grade 2 | 1 | 0 |
| Grade 3 | 2 | 4 |
| Grade 4 | 0 | 1 |
| Grade 5 | 0 | 1 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death
| Participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Grade 1 | 0 | 0 | 1 |
| Grade 2 | 0 | 0 | 2 |
| Grade 3 | 2 | 2 | 2 |
| Grade 4 | 1 | 0 | 2 |
| Grade 5 | 0 | 0 | 0 |
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
| Participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Anemia — Grade 0 to 0 | 0 | 2 |
| Anemia — Grade 0 to 1 | 1 | 0 |
| Anemia — Grade 0 to 2 | 0 | 0 |
| Anemia — Grade 0 to 3 | 0 | 0 |
| Anemia — Grade 0 to 4 | NA | NA |
| Anemia — Grade 1 to 0 | 0 | 0 |
| Anemia — Grade 1 to 1 | 2 | 3 |
| Anemia — Grade 1 to 2 | 0 | 0 |
| Anemia — Grade 1 to 3 | 0 | 0 |
| Anemia — Grade 1 to 4 | NA | NA |
| Anemia — Grade 2 to 0 | 0 | 0 |
| Anemia — Grade 2 to 1 | 0 | 0 |
| Anemia — Grade 2 to 2 | 0 | 1 |
| Anemia — Grade 2 to 3 | 0 | 0 |
| Anemia — Grade 2 to 4 | NA | NA |
| Anemia — Grade 3 to 0 | 0 | 0 |
| Anemia — Grade 3 to 1 | 0 | 0 |
| Anemia — Grade 3 to 2 | 0 | 0 |
| Anemia — Grade 3 to 3 | 0 | 0 |
| Anemia — Grade 3 to 4 | NA | NA |
| Anemia — Grade 4 to 0 | NA | NA |
| Anemia — Grade 4 to 1 | NA | NA |
| Anemia — Grade 4 to 2 | NA | NA |
| Anemia — Grade 4 to 3 | NA | NA |
| Anemia — Grade 4 to 4 | NA | NA |
| Hemoglobin increased — Grade 0 to 0 | 3 | 6 |
| Hemoglobin increased — Grade 0 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 4 | NA | NA |
| Hemoglobin increased — Grade 1 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 4 | NA | NA |
| Hemoglobin increased — Grade 2 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 4 | NA | NA |
| Hemoglobin increased — Grade 3 to 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 1 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 2 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 3 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 4 | NA | NA |
| Hemoglobin increased — Grade 4 to 0 | NA | NA |
| Hemoglobin increased — Grade 4 to 1 | NA | NA |
| Hemoglobin increased — Grade 4 to 2 | NA | NA |
| Hemoglobin increased — Grade 4 to 3 | NA | NA |
| Hemoglobin increased — Grade 4 to 4 | NA | NA |
| Leukocytosis — Grade 0 to 0 | 3 | 6 |
| Leukocytosis — Grade 0 to 1 | NA | NA |
| Leukocytosis — Grade 0 to 2 | NA | NA |
| Leukocytosis — Grade 0 to 3 | 0 | 0 |
| Leukocytosis — Grade 0 to 4 | NA | NA |
| Leukocytosis — Grade 1 to 0 | NA | NA |
| Leukocytosis — Grade 1 to 1 | NA | NA |
| Leukocytosis — Grade 1 to 2 | NA | NA |
| Leukocytosis — Grade 1 to 3 | NA | NA |
| Leukocytosis — Grade 1 to 4 | NA | NA |
| Leukocytosis — Grade 2 to 0 | NA | NA |
| Leukocytosis — Grade 2 to 1 | NA | NA |
| Leukocytosis — Grade 2 to 2 | NA | NA |
| Leukocytosis — Grade 2 to 3 | NA | NA |
| Leukocytosis — Grade 2 to 4 | NA | NA |
| Leukocytosis — Grade 3 to 0 | 0 | 0 |
| Leukocytosis — Grade 3 to 1 | NA | NA |
| Leukocytosis — Grade 3 to 2 | NA | NA |
| Leukocytosis — Grade 3 to 3 | 0 | 0 |
| Leukocytosis — Grade 3 to 4 | NA | NA |
| Leukocytosis — Grade 4 to 0 | NA | NA |
| Leukocytosis — Grade 4 to 1 | NA | NA |
| Leukocytosis — Grade 4 to 2 | NA | NA |
| Leukocytosis — Grade 4 to 3 | NA | NA |
| Leukocytosis — Grade 4 to 4 | NA | NA |
| Lymphocyte count decreased — Grade 0 to 0 | 1 | 1 |
| Lymphocyte count decreased — Grade 0 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 0 to 2 | 0 | 1 |
| Lymphocyte count decreased — Grade 0 to 3 | 0 | 1 |
| Lymphocyte count decreased — Grade 0 to 4 | 0 | 1 |
| Lymphocyte count decreased — Grade 1 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 2 | 2 | 0 |
| Lymphocyte count decreased — Grade 1 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 4 | 0 | 1 |
| Lymphocyte count decreased — Grade 2 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 2 | 0 | 1 |
| Lymphocyte count decreased — Grade 2 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 4 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 0 | 0 | 00 |
| Lymphocyte count decreased — Grade 3 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 2 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 4 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 2 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 3 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 4 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 0 | 3 | 6 |
| Lymphocyte count increased — Grade 0 to 1 | NA | NA |
| Lymphocyte count increased — Grade 0 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 4 | NA | NA |
| Lymphocyte count increased — Grade 1 to 0 | NA | NA |
| Lymphocyte count increased — Grade 1 to 1 | NA | NA |
| Lymphocyte count increased — Grade 1 to 2 | NA | NA |
| Lymphocyte count increased — Grade 1 to 3 | NA | NA |
| Lymphocyte count increased — Grade 1 to 4 | NA | NA |
| Lymphocyte count increased — Grade 2 to 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 1 | NA | NA |
| Lymphocyte count increased — Grade 2 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 4 | NA | NA |
| Lymphocyte count increased — Grade 3 to 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 1 | NA | NA |
| Lymphocyte count increased — Grade 3 to 2 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 3 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 4 | NA | NA |
| Lymphocyte count increased — Grade 4 to 0 | NA | NA |
| Lymphocyte count increased — Grade 4 to 1 | NA | NA |
| Lymphocyte count increased — Grade 4 to 2 | NA | NA |
| Lymphocyte count increased — Grade 4 to 3 | NA | NA |
| Lymphocyte count increased — Grade 4 to 4 | NA | NA |
| Neutrophil count decreased — Grade 0 to 0 | 3 | 6 |
| Neutrophil count decreased — Grade 0 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 0 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 0 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 0 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 1 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 2 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 3 to 4 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 0 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 1 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 2 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 3 | 0 | 0 |
| Neutrophil count decreased — Grade 4 to 4 | 0 | 0 |
| Platelet count decreased — Grade 0 to 0 | 2 | 5 |
| Platelet count decreased — Grade 0 to 1 | 1 | 1 |
| Platelet count decreased — Grade 0 to 2 | 0 | 0 |
| Platelet count decreased — Grade 0 to 3 | 0 | 0 |
| Platelet count decreased — Grade 0 to 4 | 0 | 0 |
| Platelet count decreased — Grade 1 to 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 1 | 0 | 0 |
| Platelet count decreased — Grade 1 to 2 | 0 | 0 |
| Platelet count decreased — Grade 1 to 3 | 0 | 0 |
| Platelet count decreased — Grade 1 to 4 | 0 | 0 |
| Platelet count decreased — Grade 2 to 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 1 | 0 | 0 |
| Platelet count decreased — Grade 2 to 2 | 0 | 0 |
| Platelet count decreased — Grade 2 to 3 | 0 | 0 |
| Platelet count decreased — Grade 2 to 4 | 0 | 0 |
| Platelet count decreased — Grade 3 to 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 1 | 0 | 0 |
| Platelet count decreased — Grade 3 to 2 | 0 | 0 |
| Platelet count decreased — Grade 3 to 3 | 0 | 0 |
| Platelet count decreased — Grade 3 to 4 | 0 | 0 |
| Platelet count decreased — Grade 4 to 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 1 | 0 | 0 |
| Platelet count decreased — Grade 4 to 2 | 0 | 0 |
| Platelet count decreased — Grade 4 to 3 | 0 | 0 |
| Platelet count decreased — Grade 4 to 4 | 0 | 0 |
| White blood cell decreased — Grade 0 to 0 | 3 | 5 |
| White blood cell decreased — Grade 0 to 1 | 0 | 1 |
| White blood cell decreased — Grade 0 to 2 | 0 | 0 |
| White blood cell decreased — Grade 0 to 3 | 0 | 0 |
| White blood cell decreased — Grade 0 to 4 | 0 | 0 |
| White blood cell decreased — Grade 1 to 0 | 0 | 0 |
| White blood cell decreased — Grade 1 to 1 | 0 | 0 |
| White blood cell decreased — Grade 1 to 2 | 0 | 0 |
| White blood cell decreased — Grade 1 to 3 | 0 | 0 |
| White blood cell decreased — Grade 1 to 4 | 0 | 0 |
| White blood cell decreased — Grade 2 to 0 | 0 | 0 |
| White blood cell decreased — Grade 2 to 1 | 0 | 0 |
| White blood cell decreased — Grade 2 to 2 | 0 | 0 |
| White blood cell decreased — Grade 2 to 3 | 0 | 0 |
| White blood cell decreased — Grade 2 to 4 | 0 | 0 |
| White blood cell decreased — Grade 3 to 0 | 0 | 0 |
| White blood cell decreased — Grade 3 to 1 | 0 | 0 |
| White blood cell decreased — Grade 3 to 2 | 0 | 0 |
| White blood cell decreased — Grade 3 to 3 | 0 | 0 |
| White blood cell decreased — Grade 3 to 4 | 0 | 0 |
| White blood cell decreased — Grade 4 to 0 | 0 | 0 |
| White blood cell decreased — Grade 4 to 1 | 0 | 0 |
| White blood cell decreased — Grade 4 to 2 | 0 | 0 |
| White blood cell decreased — Grade 4 to 3 | 0 | 0 |
| White blood cell decreased — Grade 4 to 4 | 0 | 0 |
Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
| Participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| ALT increased — Grade 0 to 0 | 1 | 5 |
| ALT increased — Grade 0 to 1 | 2 | 0 |
| ALT increased — Grade 0 to 2 | 0 | 1 |
| ALT increased — Grade 0 to 3 | 0 | 0 |
| ALT increased — Grade 0 to 4 | 0 | 0 |
| ALT increased — Grade 1 to 0 | 0 | 0 |
| ALT increased — Grade 1 to 1 | 0 | 0 |
| ALT increased — Grade 1 to 2 | 0 | 0 |
| ALT increased — Grade 1 to 3 | 0 | 0 |
| ALT increased — Grade 1 to 4 | 0 | 0 |
| ALT increased — Grade 2 to 0 | 0 | 0 |
| ALT increased — Grade 2 to 1 | 0 | 0 |
| ALT increased — Grade 2 to 2 | 0 | 0 |
| ALT increased — Grade 2 to 3 | 0 | 0 |
| ALT increased — Grade 2 to 4 | 0 | 0 |
| ALT increased — Grade 3 to 0 | 0 | 0 |
| ALT increased — Grade 3 to 1 | 0 | 0 |
| ALT increased — Grade 3 to 2 | 0 | 0 |
| ALT increased — Grade 3 to 3 | 0 | 0 |
| ALT increased — Grade 3 to 4 | 0 | 0 |
| ALT increased — Grade 4 to 0 | 0 | 0 |
| ALT increased — Grade 4 to 1 | 0 | 0 |
| ALT increased — Grade 4 to 2 | 0 | 0 |
| ALT increased — Grade 4 to 3 | 0 | 0 |
| ALT increased — Grade 4 to 4 | 0 | 0 |
| ALP increased — Grade 0 to 0 | 2 | 4 |
| ALP increased — Grade 0 to 1 | 0 | 2 |
| ALP increased — Grade 0 to 2 | 0 | 0 |
| ALP increased — Grade 0 to 3 | 0 | 0 |
| ALP increased — Grade 0 to 4 | 0 | 0 |
| ALP increased — Grade 1 to 0 | 0 | 0 |
| ALP increased — Grade 1 to 1 | 0 | 0 |
| ALP increased — Grade 1 to 2 | 1 | 0 |
| ALP increased — Grade 1 to 3 | 0 | 0 |
| ALP increased — Grade 1 to 4 | 0 | 0 |
| ALP increased — Grade 2 to 0 | 0 | 0 |
| ALP increased — Grade 2 to 1 | 0 | 0 |
| ALP increased — Grade 2 to 2 | 0 | 0 |
| ALP increased — Grade 2 to 3 | 0 | 0 |
| ALP increased — Grade 2 to 4 | 0 | 0 |
| ALP increased — Grade 3 to 0 | 0 | 0 |
| ALP increased — Grade 3 to 1 | 0 | 0 |
| ALP increased — Grade 3 to 2 | 0 | 0 |
| ALP increased — Grade 3 to 3 | 0 | 0 |
| ALP increased — Grade 3 to 4 | 0 | 0 |
| ALP increased — Grade 4 to 0 | 0 | 0 |
| ALP increased — Grade 4 to 1 | 0 | 0 |
| ALP increased — Grade 4 to 2 | 0 | 0 |
| ALP increased — Grade 4 to 3 | 0 | 0 |
| ALP increased — Grade 4 to 4 | 0 | 0 |
| AST increased — Grade 0 to 0 | 0 | 5 |
| AST increased — Grade 0 to 1 | 1 | 0 |
| AST increased — Grade 0 to 2 | 0 | 0 |
| AST increased — Grade 0 to 3 | 0 | 1 |
| AST increased — Grade 0 to 4 | 0 | 0 |
| AST increased — Grade 1 to 0 | 1 | 0 |
| AST increased — Grade 1 to 1 | 1 | 0 |
| AST increased — Grade 1 to 2 | 0 | 0 |
| AST increased — Grade 1 to 3 | 0 | 0 |
| AST increased — Grade 1 to 4 | 0 | 0 |
| AST increased — Grade 2 to 0 | 0 | 0 |
| AST increased — Grade 2 to 1 | 0 | 0 |
| AST increased — Grade 2 to 2 | 0 | 0 |
| AST increased — Grade 2 to 3 | 0 | 0 |
| AST increased — Grade 2 to 4 | 0 | 0 |
| AST increased — Grade 3 to 0 | 0 | 0 |
| AST increased — Grade 3 to 1 | 0 | 0 |
| AST increased — Grade 3 to 2 | 0 | 0 |
| AST increased — Grade 3 to 3 | 0 | 0 |
| AST increased — Grade 3 to 4 | 0 | 0 |
| AST increased — Grade 4 to 0 | 0 | 0 |
| AST increased — Grade 4 to 1 | 0 | 0 |
| AST increased — Grade 4 to 2 | 0 | 0 |
| AST increased — Grade 4 to 3 | 0 | 0 |
| AST increased — Grade 4 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 0 | 3 | 6 |
| Blood bilirubin increased — Grade 0 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 4 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 1 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 2 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 3 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 4 | 0 | 0 |
| CPK increased — Grade 0 to 0 | 3 | 5 |
| CPK increased — Grade 0 to 1 | 0 | 0 |
| CPK increased — Grade 0 to 2 | 0 | 0 |
| CPK increased — Grade 0 to 3 | 0 | 0 |
| CPK increased — Grade 0 to 4 | 0 | 0 |
| CPK increased — Grade 1 to 0 | 0 | 1 |
| CPK increased — Grade 1 to 1 | 0 | 0 |
| CPK increased — Grade 1 to 2 | 0 | 0 |
| CPK increased — Grade 1 to 3 | 0 | 0 |
| CPK increased — Grade 1 to 4 | 0 | 0 |
| CPK increased — Grade 2 to 0 | 0 | 0 |
| CPK increased — Grade 2 to 1 | 0 | 0 |
| CPK increased — Grade 2 to 2 | 0 | 0 |
| CPK increased — Grade 2 to 3 | 0 | 0 |
| CPK increased — Grade 2 to 4 | 0 | 0 |
| CPK increased — Grade 3 to 0 | 0 | 0 |
| CPK increased — Grade 3 to 1 | 0 | 0 |
| CPK increased — Grade 3 to 2 | 0 | 0 |
| CPK increased — Grade 3 to 3 | 0 | 0 |
| CPK increased — Grade 3 to 4 | 0 | 0 |
| CPK increased — Grade 4 to 0 | 0 | 0 |
| CPK increased — Grade 4 to 1 | 0 | 0 |
| CPK increased — Grade 4 to 2 | 0 | 0 |
| CPK increased — Grade 4 to 3 | 0 | 0 |
| CPK increased — Grade 4 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 0 | 1 | 0 |
| Chronic kidney disease — Grade 0 to 1 | 1 | 2 |
| Chronic kidney disease — Grade 0 to 2 | 0 | 1 |
| Chronic kidney disease — Grade 0 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 2 | 00 | 1 |
| Chronic kidney disease — Grade 1 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 2 | 1 | 2 |
| Chronic kidney disease — Grade 2 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 2 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 4 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 1 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 2 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 3 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 4 | 0 | 0 |
| Creatinine increased — Grade 0 to 0 | 2 | 3 |
| Creatinine increased — Grade 0 to 1 | 0 | 0 |
| Creatinine increased — Grade 0 to 2 | 0 | 0 |
| Creatinine increased — Grade 0 to 3 | 0 | 0 |
| Creatinine increased — Grade 0 to 4 | 0 | 0 |
| Creatinine increased — Grade 1 to 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 1 | 1 | 2 |
| Creatinine increased — Grade 1 to 2 | 0 | 1 |
| Creatinine increased — Grade 1 to 3 | 0 | 0 |
| Creatinine increased — Grade 1 to 4 | 0 | 0 |
| Creatinine increased — Grade 2 to 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 1 | 0 | 0 |
| Creatinine increased — Grade 2 to 2 | 0 | 0 |
| Creatinine increased — Grade 2 to 3 | 0 | 0 |
| Creatinine increased — Grade 2 to 4 | 0 | 0 |
| Creatinine increased — Grade 3 to 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 1 | 0 | 0 |
| Creatinine increased — Grade 3 to 2 | 0 | 0 |
| Creatinine increased — Grade 3 to 3 | 0 | 0 |
| Creatinine increased — Grade 3 to 4 | 0 | 0 |
| Creatinine increased — Grade 4 to 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 1 | 0 | 0 |
| Creatinine increased — Grade 4 to 2 | 0 | 0 |
| Creatinine increased — Grade 4 to 3 | 0 | 0 |
| Creatinine increased — Grade 4 to 4 | 0 | 0 |
| Hypercalcemia — Grade 0 to 0 | 1 | 5 |
| Hypercalcemia — Grade 0 to 1 | 2 | 1 |
| Hypercalcemia — Grade 0 to 2 | 0 | 0 |
| Hypercalcemia — Grade 0 to 3 | 0 | 0 |
| Hypercalcemia — Grade 0 to 4 | 0 | 0 |
| Hypercalcemia — Grade 1 to 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 1 | 0 | 0 |
| Hypercalcemia — Grade 1 to 2 | 0 | 0 |
| Hypercalcemia — Grade 1 to 3 | 0 | 0 |
| Hypercalcemia — Grade 1 to 4 | 0 | 0 |
| Hypercalcemia — Grade 2 to 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 1 | 0 | 0 |
| Hypercalcemia — Grade 2 to 2 | 0 | 0 |
| Hypercalcemia — Grade 2 to 3 | 0 | 0 |
| Hypercalcemia — Grade 2 to 4 | 0 | 0 |
| Hypercalcemia — Grade 3 to 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 1 | 0 | 0 |
| Hypercalcemia — Grade 3 to 2 | 0 | 0 |
| Hypercalcemia — Grade 3 to 3 | 0 | 0 |
| Hypercalcemia — Grade 3 to 4 | 0 | 0 |
| Hypercalcemia — Grade 4 to 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 1 | 0 | 0 |
| Hypercalcemia — Grade 4 to 2 | 0 | 0 |
| Hypercalcemia — Grade 4 to 3 | 0 | 0 |
| Hypercalcemia — Grade 4 to 4 | 0 | 0 |
| Hyperkalemia — Grade 0 to 0 | 2 | 5 |
| Hyperkalemia — Grade 0 to 1 | 1 | 1 |
| Hyperkalemia — Grade 0 to 2 | 0 | 0 |
| Hyperkalemia — Grade 0 to 3 | 0 | 0 |
| Hyperkalemia — Grade 0 to 4 | 0 | 0 |
| Hyperkalemia — Grade 1 to 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 1 | 0 | 0 |
| Hyperkalemia — Grade 1 to 2 | 0 | 0 |
| Hyperkalemia — Grade 1 to 3 | 0 | 0 |
| Hyperkalemia — Grade 1 to 4 | 0 | 0 |
| Hyperkalemia — Grade 2 to 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 1 | 0 | 0 |
| Hyperkalemia — Grade 2 to 2 | 0 | 0 |
| Hyperkalemia — Grade 2 to 3 | 0 | 0 |
| Hyperkalemia — Grade 2 to 4 | 0 | 0 |
| Hyperkalemia — Grade 3 to 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 1 | 0 | 0 |
| Hyperkalemia — Grade 3 to 2 | 0 | 0 |
| Hyperkalemia — Grade 3 to 3 | 0 | 0 |
| Hyperkalemia — Grade 3 to 4 | 0 | 0 |
| Hyperkalemia — Grade 4 to 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 1 | 0 | 0 |
| Hyperkalemia — Grade 4 to 2 | 0 | 0 |
| Hyperkalemia — Grade 4 to 3 | 0 | 0 |
| Hyperkalemia — Grade 4 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 0 | 3 | 6 |
| Hypermagnesemia — Grade 0 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 2 | NA | NA |
| Hypermagnesemia — Grade 0 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 2 | NA | NA |
| Hypermagnesemia — Grade 1 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 2 to 0 | NA | NA |
| Hypermagnesemia — Grade 2 to 1 | NA | NA |
| Hypermagnesemia — Grade 2 to 2 | NA | NA |
| Hypermagnesemia — Grade 2 to 3 | NA | NA |
| Hypermagnesemia — Grade 2 to 4 | NA | NA |
| Hypermagnesemia — Grade 3 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 2 | NA | NA |
| Hypermagnesemia — Grade 3 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 4 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 1 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 2 | NA | NA |
| Hypermagnesemia — Grade 4 to 3 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 4 | 0 | 0 |
| Hypernatremia — Grade 0 to 0 | 3 | 6 |
| Hypernatremia — Grade 0 to 1 | 0 | 0 |
| Hypernatremia — Grade 0 to 2 | 0 | 0 |
| Hypernatremia — Grade 0 to 3 | 0 | 0 |
| Hypernatremia — Grade 0 to 4 | 0 | 0 |
| Hypernatremia — Grade 1 to 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 1 | 0 | 0 |
| Hypernatremia — Grade 1 to 2 | 0 | 0 |
| Hypernatremia — Grade 1 to 3 | 0 | 0 |
| Hypernatremia — Grade 1 to 4 | 0 | 0 |
| Hypernatremia — Grade 2 to 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 1 | 0 | 0 |
| Hypernatremia — Grade 2 to 2 | 0 | 0 |
| Hypernatremia — Grade 2 to 3 | 0 | 0 |
| Hypernatremia — Grade 2 to 4 | 0 | 0 |
| Hypernatremia — Grade 3 to 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 1 | 0 | 0 |
| Hypernatremia — Grade 3 to 2 | 0 | 0 |
| Hypernatremia — Grade 3 to 3 | 0 | 0 |
| Hypernatremia — Grade 3 to 4 | 0 | 0 |
| Hypernatremia — Grade 4 to 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 1 | 0 | 0 |
| Hypernatremia — Grade 4 to 2 | 0 | 0 |
| Hypernatremia — Grade 4 to 3 | 0 | 0 |
| Hypernatremia — Grade 4 to 4 | 0 | 0 |
| Hypoalbuminemia — Grade 0 to 0 | 2 | 2 |
| Hypoalbuminemia — Grade 0 to 1 | 1 | 1 |
| Hypoalbuminemia — Grade 0 to 2 | 0 | 1 |
| Hypoalbuminemia — Grade 0 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 0 to 4 | NA | NA |
| Hypoalbuminemia — Grade 1 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 1 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 2 | 0 | 1 |
| Hypoalbuminemia — Grade 1 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 4 | NA | NA |
| Hypoalbuminemia — Grade 2 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 1 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 2 | 0 | 1 |
| Hypoalbuminemia — Grade 2 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 4 | NA | NA |
| Hypoalbuminemia — Grade 3 to 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 1 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 2 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 3 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 4 | NA | NA |
| Hypoalbuminemia — Grade 4 to 0 | NA | NA |
| Hypoalbuminemia — Grade 4 to 1 | NA | NA |
| Hypoalbuminemia — Grade 4 to 2 | NA | NA |
| Hypoalbuminemia — Grade 4 to 3 | NA | NA |
| Hypoalbuminemia — Grade 4 to 4 | NA | NA |
| Hypocalcemia — Grade 0 to 0 | 3 | 6 |
| Hypocalcemia — Grade 0 to 1 | 0 | 0 |
| Hypocalcemia — Grade 0 to 2 | 0 | 0 |
| Hypocalcemia — Grade 0 to 3 | 0 | 0 |
| Hypocalcemia — Grade 0 to 4 | 0 | 0 |
| Hypocalcemia — Grade 1 to 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 1 | 0 | 0 |
| Hypocalcemia — Grade 1 to 2 | 0 | 0 |
| Hypocalcemia — Grade 1 to 3 | 0 | 0 |
| Hypocalcemia — Grade 1 to 4 | 0 | 0 |
| Hypocalcemia — Grade 2 to 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 1 | 0 | 0 |
| Hypocalcemia — Grade 2 to 2 | 0 | 0 |
| Hypocalcemia — Grade 2 to 3 | 0 | 0 |
| Hypocalcemia — Grade 2 to 4 | 0 | 0 |
| Hypocalcemia — Grade 3 to 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 1 | 0 | 0 |
| Hypocalcemia — Grade 3 to 2 | 0 | 0 |
| Hypocalcemia — Grade 3 to 3 | 0 | 0 |
| Hypocalcemia — Grade 3 to 4 | 0 | 0 |
| Hypocalcemia — Grade 4 to 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 1 | 0 | 0 |
| Hypocalcemia — Grade 4 to 2 | 0 | 0 |
| Hypocalcemia — Grade 4 to 3 | 0 | 0 |
| Hypocalcemia — Grade 4 to 4 | 0 | 0 |
| Hypoglycemia — Grade 0 to 0 | 2 | 5 |
| Hypoglycemia — Grade 0 to 1 | 1 | 1 |
| Hypoglycemia — Grade 0 to 2 | 0 | 0 |
| Hypoglycemia — Grade 0 to 3 | 0 | 0 |
| Hypoglycemia — Grade 0 to 4 | 0 | 0 |
| Hypoglycemia — Grade 1 to 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 1 | 0 | 0 |
| Hypoglycemia — Grade 1 to 2 | 0 | 0 |
| Hypoglycemia — Grade 1 to 3 | 0 | 0 |
| Hypoglycemia — Grade 1 to 4 | 0 | 0 |
| Hypoglycemia — Grade 2 to 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 1 | 0 | 0 |
| Hypoglycemia — Grade 2 to 2 | 0 | 0 |
| Hypoglycemia — Grade 2 to 3 | 0 | 0 |
| Hypoglycemia — Grade 2 to 4 | 0 | 0 |
| Hypoglycemia — Grade 3 to 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 1 | 0 | 0 |
| Hypoglycemia — Grade 3 to 2 | 0 | 0 |
| Hypoglycemia — Grade 3 to 3 | 0 | 0 |
| Hypoglycemia — Grade 3 to 4 | 0 | 0 |
| Hypoglycemia — Grade 4 to 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 1 | 0 | 0 |
| Hypoglycemia — Grade 4 to 2 | 0 | 0 |
| Hypoglycemia — Grade 4 to 3 | 0 | 0 |
| Hypoglycemia — Grade 4 to 4 | 0 | 0 |
| Hypokalemia — Grade 0 to 0 | 2 | 4 |
| Hypokalemia — Grade 0 to 1 | NA | NA |
| Hypokalemia — Grade 0 to 2 | 1 | 2 |
| Hypokalemia — Grade 0 to 3 | 0 | 0 |
| Hypokalemia — Grade 0 to 4 | 0 | 0 |
| Hypokalemia — Grade 1 to 0 | NA | NA |
| Hypokalemia — Grade 1 to 1 | NA | NA |
| Hypokalemia — Grade 1 to 2 | NA | NA |
| Hypokalemia — Grade 1 to 3 | NA | NA |
| Hypokalemia — Grade 1 to 4 | NA | NA |
| Hypokalemia — Grade 2 to 0 | 0 | 0 |
| Hypokalemia — Grade 2 to 1 | NA | NA |
| Hypokalemia — Grade 2 to 2 | 0 | 0 |
| Hypokalemia — Grade 2 to 3 | 0 | 0 |
| Hypokalemia — Grade 2 to 4 | 0 | 0 |
| Hypokalemia — Grade 3 to 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 1 | NA | NA |
| Hypokalemia — Grade 3 to 2 | 0 | 0 |
| Hypokalemia — Grade 3 to 3 | 0 | 0 |
| Hypokalemia — Grade 3 to 4 | 0 | 0 |
| Hypokalemia — Grade 4 to 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 1 | NA | NA |
| Hypokalemia — Grade 4 to 2 | 0 | 0 |
| Hypokalemia — Grade 4 to 3 | 0 | 0 |
| Hypokalemia — Grade 4 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 0 | 1 | 5 |
| Hypomagnesemia — Grade 0 to 1 | 1 | 1 |
| Hypomagnesemia — Grade 0 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 1 | 1 | 0 |
| Hypomagnesemia — Grade 2 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 4 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 1 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 2 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 3 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 4 | 0 | 0 |
| Hyponatremia — Grade 0 to 0 | 2 | 4 |
| Hyponatremia — Grade 0 to 1 | 1 | 2 |
| Hyponatremia — Grade 0 to 2 | NA | NA |
| Hyponatremia — Grade 0 to 3 | 0 | 0 |
| Hyponatremia — Grade 0 to 4 | 0 | 0 |
| Hyponatremia — Grade 1 to 0 | 0 | 0 |
| Hyponatremia — Grade 1 to 1 | 0 | 0 |
| Hyponatremia — Grade 1 to 2 | NA | NA |
| Hyponatremia — Grade 1 to 3 | 0 | 0 |
| Hyponatremia — Grade 1 to 4 | 0 | 0 |
| Hyponatremia — Grade 2 to 0 | NA | NA |
| Hyponatremia — Grade 2 to 1 | NA | NA |
| Hyponatremia — Grade 2 to 2 | NA | NA |
| Hyponatremia — Grade 2 to 3 | NA | NA |
| Hyponatremia — Grade 2 to 4 | NA | NA |
| Hyponatremia — Grade 3 to 0 | 0 | 0 |
| Hyponatremia — Grade 3 to 1 | 0 | 0 |
| Hyponatremia — Grade 3 to 2 | NA | NA |
| Hyponatremia — Grade 3 to 3 | 0 | 0 |
| Hyponatremia — Grade 3 to 4 | 0 | 0 |
| Hyponatremia — Grade 4 to 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 1 | 0 | 0 |
| Hyponatremia — Grade 4 to 2 | NA | NA |
| Hyponatremia — Grade 4 to 3 | 0 | 0 |
| Hyponatremia — Grade 4 to 4 | 0 | 0 |
| Lipase increased — Grade 0 to 0 | 3 | 4 |
| Lipase increased — Grade 0 to 1 | 0 | 2 |
| Lipase increased — Grade 0 to 2 | 0 | 0 |
| Lipase increased — Grade 0 to 3 | 0 | 0 |
| Lipase increased — Grade 0 to 4 | 0 | 0 |
| Lipase increased — Grade 1 to 0 | 0 | 0 |
| Lipase increased — Grade 1 to 1 | 0 | 0 |
| Lipase increased — Grade 1 to 2 | 0 | 0 |
| Lipase increased — Grade 1 to 3 | 0 | 0 |
| Lipase increased — Grade 1 to 4 | 0 | 0 |
| Lipase increased — Grade 2 to 0 | 0 | 0 |
| Lipase increased — Grade 2 to 1 | 0 | 0 |
| Lipase increased — Grade 2 to 2 | 0 | 0 |
| Lipase increased — Grade 2 to 3 | 0 | 0 |
| Lipase increased — Grade 2 to 4 | 0 | 0 |
| Lipase increased — Grade 3 to 0 | 0 | 0 |
| Lipase increased — Grade 3 to 1 | 0 | 0 |
| Lipase increased — Grade 3 to 2 | 0 | 0 |
| Lipase increased — Grade 3 to 3 | 0 | 0 |
| Lipase increased — Grade 3 to 4 | 0 | 0 |
| Lipase increased — Grade 4 to 0 | 0 | 0 |
| Lipase increased — Grade 4 to 1 | 0 | 0 |
| Lipase increased — Grade 4 to 2 | 0 | 0 |
| Lipase increased — Grade 4 to 3 | 0 | 0 |
| Lipase increased — Grade 4 to 4 | 0 | 0 |
| Serum amylase increased — Grade 0 to 0 | 3 | 4 |
| Serum amylase increased — Grade 0 to 1 | 0 | 1 |
| Serum amylase increased — Grade 0 to 2 | 0 | 0 |
| Serum amylase increased — Grade 0 to 3 | 0 | 0 |
| Serum amylase increased — Grade 0 to 4 | 0 | 0 |
| Serum amylase increased — Grade 1 to 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 1 | 0 | 0 |
| Serum amylase increased — Grade 1 to 2 | 0 | 1 |
| Serum amylase increased — Grade 1 to 3 | 0 | 0 |
| Serum amylase increased — Grade 1 to 4 | 0 | 0 |
| Serum amylase increased — Grade 2 to 0 | 0 | 0 |
| Serum amylase increased — Grade 2 to 1 | 0 | 0 |
| Serum amylase increased — Grade 2 to 2 | 0 | 0 |
| Serum amylase increased — Grade 2 to 3 | 0 | 0 |
| Serum amylase increased — Grade 2 to 4 | 0 | 0 |
| Serum amylase increased — Grade 3 to 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 1 | 0 | 0 |
| Serum amylase increased — Grade 3 to 2 | 0 | 0 |
| Serum amylase increased — Grade 3 to 3 | 0 | 0 |
| Serum amylase increased — Grade 3 to 4 | 0 | 0 |
| Serum amylase increased — Grade 4 to 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 1 | 0 | 0 |
| Serum amylase increased — Grade 4 to 2 | 0 | 0 |
| Serum amylase increased — Grade 4 to 3 | 0 | 0 |
| Serum amylase increased — Grade 4 to 4 | 0 | 0 |
Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Anemia — Grade 0 to 0 | 1 | 0 | 5 |
| Anemia — Grade 0 to 1 | 1 | 0 | 0 |
| Anemia — Grade 0 to 2 | 0 | 0 | 0 |
| Anemia — Grade 0 to 3 | 0 | 0 | 0 |
| Anemia — Grade 0 to 4 | NA | NA | NA |
| Anemia — Grade 1 to 0 | 0 | 0 | 1 |
| Anemia — Grade 1 to 1 | 0 | 2 | 1 |
| Anemia — Grade 1 to 2 | 0 | 0 | 0 |
| Anemia — Grade 1 to 3 | 0 | 0 | 0 |
| Anemia — Grade 1 to 4 | NA | NA | NA |
| Anemia — Grade 2 to 0 | 0 | 0 | 0 |
| Anemia — Grade 2 to 1 | 0 | 0 | 0 |
| Anemia — Grade 2 to 2 | 1 | 0 | 0 |
| Anemia — Grade 2 to 3 | 0 | 0 | 0 |
| Anemia — Grade 2 to 4 | NA | NA | NA |
| Anemia — Grade 3 to 0 | 0 | 0 | 0 |
| Anemia — Grade 3 to 1 | 0 | 0 | 0 |
| Anemia — Grade 3 to 2 | 0 | 0 | 0 |
| Anemia — Grade 3 to 3 | 0 | 0 | 0 |
| Anemia — Grade 3 to 4 | NA | NA | NA |
| Anemia — Grade 4 to 0 | NA | NA | NA |
| Anemia — Grade 4 to 1 | NA | NA | NA |
| Anemia — Grade 4 to 2 | NA | NA | NA |
| Anemia — Grade 4 to 3 | NA | NA | NA |
| Anemia — Grade 4 to 4 | NA | NA | NA |
| Hemoglobin increased — Grade 0 to 0 | 3 | 2 | 6 |
| Hemoglobin increased — Grade 0 to 1 | 0 | 0 | 1 |
| Hemoglobin increased — Grade 0 to 2 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 3 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 0 to 4 | NA | NA | NA |
| Hemoglobin increased — Grade 1 to 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 1 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 2 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 3 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 1 to 4 | NA | NA | NA |
| Hemoglobin increased — Grade 2 to 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 1 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 2 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 3 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 2 to 4 | NA | NA | NA |
| Hemoglobin increased — Grade 3 to 0 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 1 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 2 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 3 | 0 | 0 | 0 |
| Hemoglobin increased — Grade 3 to 4 | NA | NA | NA |
| Hemoglobin increased — Grade 4 to 0 | NA | NA | NA |
| Hemoglobin increased — Grade 4 to 1 | NA | NA | NA |
| Hemoglobin increased — Grade 4 to 2 | NA | NA | NA |
| Hemoglobin increased — Grade 4 to 3 | NA | NA | NA |
| Hemoglobin increased — Grade 4 to 4 | NA | NA | NA |
| Leukocytosis — Grade 0 to 0 | 3 | 2 | 7 |
| Leukocytosis — Grade 0 to 1 | NA | NA | NA |
| Leukocytosis — Grade 0 to 2 | NA | NA | NA |
| Leukocytosis — Grade 0 to 3 | 0 | 0 | 0 |
| Leukocytosis — Grade 0 to 4 | NA | NA | NA |
| Leukocytosis — Grade 1 to 0 | NA | NA | NA |
| Leukocytosis — Grade 1 to 1 | NA | NA | NA |
| Leukocytosis — Grade 1 to 2 | NA | NA | NA |
| Leukocytosis — Grade 1 to 3 | NA | NA | NA |
| Leukocytosis — Grade 1 to 4 | NA | NA | NA |
| Leukocytosis — Grade 2 to 0 | NA | NA | NA |
| Leukocytosis — Grade 2 to 1 | NA | NA | NA |
| Leukocytosis — Grade 2 to 2 | NA | NA | NA |
| Leukocytosis — Grade 2 to 3 | NA | NA | NA |
| Leukocytosis — Grade 2 to 4 | NA | NA | NA |
| Leukocytosis — Grade 3 to 0 | 0 | 0 | 0 |
| Leukocytosis — Grade 3 to 1 | NA | NA | NA |
| Leukocytosis — Grade 3 to 2 | NA | NA | NA |
| Leukocytosis — Grade 3 to 3 | 0 | 0 | 0 |
| Leukocytosis — Grade 3 to 4 | NA | NA | NA |
| Leukocytosis — Grade 4 to 0 | NA | NA | NA |
| Leukocytosis — Grade 4 to 1 | NA | NA | NA |
| Leukocytosis — Grade 4 to 2 | NA | NA | NA |
| Leukocytosis — Grade 4 to 3 | NA | NA | NA |
| Leukocytosis — Grade 4 to 4 | NA | NA | NA |
| Lymphocyte count decreased — Grade 0 to 0 | 0 | 0 | 3 |
| Lymphocyte count decreased — Grade 0 to 1 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 0 to 2 | 0 | 0 | 2 |
| Lymphocyte count decreased — Grade 0 to 3 | 1 | 1 | 0 |
| Lymphocyte count decreased — Grade 0 to 4 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 1 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 1 to 2 | 0 | 1 | 0 |
| Lymphocyte count decreased — Grade 1 to 3 | 1 | 0 | 1 |
| Lymphocyte count decreased — Grade 1 to 4 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 1 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 2 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 3 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 2 to 4 | 1 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 1 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 2 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 3 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 3 to 4 | 0 | 0 | 1 |
| Lymphocyte count decreased — Grade 4 to 0 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 1 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 2 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 3 | 0 | 0 | 0 |
| Lymphocyte count decreased — Grade 4 to 4 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 0 | 3 | 2 | 7 |
| Lymphocyte count increased — Grade 0 to 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 0 to 2 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 3 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 0 to 4 | NA | NA | NA |
| Lymphocyte count increased — Grade 1 to 0 | NA | NA | NA |
| Lymphocyte count increased — Grade 1 to 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 1 to 2 | NA | NA | NA |
| Lymphocyte count increased — Grade 1 to 3 | NA | NA | NA |
| Lymphocyte count increased — Grade 1 to 4 | NA | NA | NA |
| Lymphocyte count increased — Grade 2 to 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 2 to 2 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 3 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 2 to 4 | NA | NA | NA |
| Lymphocyte count increased — Grade 3 to 0 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 3 to 2 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 3 | 0 | 0 | 0 |
| Lymphocyte count increased — Grade 3 to 4 | NA | NA | NA |
| Lymphocyte count increased — Grade 4 to 0 | NA | NA | NA |
| Lymphocyte count increased — Grade 4 to 1 | NA | NA | NA |
| Lymphocyte count increased — Grade 4 to 2 | NA | NA | NA |
| Lymphocyte count increased — Grade 4 to 3 | NA | NA | NA |
| Lymphocyte count increased — Grade 4 to 4 | NA | NA | NA |
| Neutrophil count decrease — Grade 0 to 0 | 2 | 2 | 7 |
| Neutrophil count decrease — Grade 0 to 1 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 0 to 2 | 1 | 0 | 0 |
| Neutrophil count decrease — Grade 0 to 3 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 0 to 4 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 1 to 0 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 1 to 1 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 1 to 2 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 1 to 3 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 1 to 4 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 2 to 0 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 2 to 1 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 2 to 2 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 2 to 3 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 2 to 4 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 3 to 0 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 3 to 1 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 3 to 2 | 0 | 00 | 0 |
| Neutrophil count decrease — Grade 3 to 3 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 3 to 4 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 4 to 0 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 4 to 1 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 4 to 2 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 4 to 3 | 0 | 0 | 0 |
| Neutrophil count decrease — Grade 4 to 4 | 0 | 0 | 0 |
| Platelet count decreased — Grade 0 to 0 | 2 | 2 | 6 |
| Platelet count decreased — Grade 0 to 1 | 0 | 0 | 0 |
| Platelet count decreased — Grade 0 to 2 | 1 | 0 | 1 |
| Platelet count decreased — Grade 0 to 3 | 0 | 0 | 0 |
| Platelet count decreased — Grade 0 to 4 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 1 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 2 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 3 | 0 | 0 | 0 |
| Platelet count decreased — Grade 1 to 4 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 1 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 2 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 3 | 0 | 0 | 0 |
| Platelet count decreased — Grade 2 to 4 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 1 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 2 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 3 | 0 | 0 | 0 |
| Platelet count decreased — Grade 3 to 4 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 0 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 1 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 2 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 3 | 0 | 0 | 0 |
| Platelet count decreased — Grade 4 to 4 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 0 to 0 | 1 | 1 | 5 |
| White blood Cell decreased — Grade 0 to 1 | 1 | 0 | 2 |
| White blood Cell decreased — Grade 0 to 2 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 0 to 3 | 1 | 0 | 0 |
| White blood Cell decreased — Grade 0 to 4 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 1 to 0 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 1 to 1 | 0 | 1 | 0 |
| White blood Cell decreased — Grade 1 to 2 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 1 to 3 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 1 to 4 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 2 to 0 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 2 to 1 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 2 to 2 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 2 to 3 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 2 to 4 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 3 to 0 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 3 to 1 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 3 to 2 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 3 to 3 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 3 to 4 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 4 to 0 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 4 to 1 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 4 to 2 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 4 to 3 | 0 | 0 | 0 |
| White blood Cell decreased — Grade 4 to 4 | 0 | 0 | 0 |
Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
| Participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| ALT increased — Grade 0 to 0 | 1 | 1 | 3 |
| ALT increased — Grade 0 to 1 | 1 | 0 | 3 |
| ALT increased — Grade 0 to 2 | 0 | 0 | 0 |
| ALT increased — Grade 0 to 3 | 1 | 1 | 0 |
| ALT increased — Grade 0 to 4 | 0 | 0 | 1 |
| ALT increased — Grade 1 to 0 | 0 | 0 | 0 |
| ALT increased — Grade 1 to 1 | 0 | 0 | 0 |
| ALT increased — Grade 1 to 2 | 0 | 0 | 0 |
| ALT increased — Grade 1 to 3 | 0 | 0 | 0 |
| ALT increased — Grade 1 to 4 | 0 | 0 | 0 |
| ALT increased — Grade 2 to 0 | 0 | 0 | 0 |
| ALT increased — Grade 2 to 1 | 0 | 0 | 0 |
| ALT increased — Grade 2 to 2 | 0 | 0 | 0 |
| ALT increased — Grade 2 to 3 | 0 | 0 | 0 |
| ALT increased — Grade 2 to 4 | 0 | 0 | 0 |
| ALT increased — Grade 3 to 0 | 0 | 0 | 0 |
| ALT increased — Grade 3 to 1 | 0 | 0 | 0 |
| ALT increased — Grade 3 to 2 | 0 | 0 | 0 |
| ALT increased — Grade 3 to 3 | 0 | 0 | 0 |
| ALT increased — Grade 3 to 4 | 0 | 0 | 0 |
| ALT increased — Grade 4 to 0 | 0 | 0 | 0 |
| ALT increased — Grade 4 to 1 | 0 | 0 | 0 |
| ALT increased — Grade 4 to 2 | 0 | 0 | 0 |
| ALT increased — Grade 4 to 3 | 0 | 0 | 0 |
| ALT increased — Grade 4 to 4 | 0 | 0 | 0 |
| ALP increased — Grade 0 to 0 | 0 | 1 | 3 |
| ALP increased — Grade 0 to 1 | 2 | 1 | 2 |
| ALP increased — Grade 0 to 2 | 0 | 0 | 0 |
| ALP increased — Grade 0 to 3 | 0 | 0 | 0 |
| ALP increased — Grade 0 to 4 | 0 | 0 | 0 |
| ALP increased — Grade 1 to 0 | 1 | 0 | 2 |
| ALP increased — Grade 1 to 1 | 0 | 0 | 0 |
| ALP increased — Grade 1 to 2 | 0 | 0 | 0 |
| ALP increased — Grade 1 to 3 | 0 | 0 | 0 |
| ALP increased — Grade 1 to 4 | 0 | 0 | 0 |
| ALP increased — Grade 2 to 0 | 0 | 0 | 0 |
| ALP increased — Grade 2 to 1 | 0 | 0 | 0 |
| ALP increased — Grade 2 to 2 | 0 | 0 | 0 |
| ALP increased — Grade 2 to 3 | 0 | 0 | 0 |
| ALP increased — Grade 2 to 4 | 0 | 0 | 0 |
| ALP increased — Grade 3 to 0 | 0 | 0 | 0 |
| ALP increased — Grade 3 to 1 | 0 | 0 | 0 |
| ALP increased — Grade 3 to 2 | 0 | 0 | 0 |
| ALP increased — Grade 3 to 3 | 0 | 0 | 0 |
| ALP increased — Grade 3 to 4 | 0 | 0 | 0 |
| ALP increased — Grade 4 to 0 | 0 | 0 | 0 |
| ALP increased — Grade 4 to 1 | 0 | 0 | 0 |
| ALP increased — Grade 4 to 2 | 0 | 0 | 0 |
| ALP increased — Grade 4 to 3 | 0 | 0 | 0 |
| ALP increased — Grade 4 to 4 | 0 | 0 | 0 |
| AST increase — Grade 0 to 0 | 1 | 1 | 2 |
| AST increase — Grade 0 to 1 | 1 | 0 | 4 |
| AST increase — Grade 0 to 2 | 0 | 0 | 0 |
| AST increase — Grade 0 to 3 | 1 | 1 | 0 |
| AST increase — Grade 0 to 4 | 0 | 0 | 1 |
| AST increase — Grade 1 to 0 | 0 | 0 | 0 |
| AST increase — Grade 1 to 1 | 0 | 0 | 0 |
| AST increase — Grade 1 to 2 | 0 | 0 | 0 |
| AST increase — Grade 1 to 3 | 0 | 0 | 0 |
| AST increase — Grade 1 to 4 | 0 | 0 | 0 |
| AST increase — Grade 2 to 0 | 0 | 0 | 0 |
| AST increase — Grade 2 to 1 | 0 | 0 | 0 |
| AST increase — Grade 2 to 2 | 0 | 0 | 0 |
| AST increase — Grade 2 to 3 | 0 | 0 | 0 |
| AST increase — Grade 2 to 4 | 0 | 0 | 0 |
| AST increase — Grade 3 to 0 | 0 | 0 | 0 |
| AST increase — Grade 3 to 1 | 0 | 0 | 0 |
| AST increase — Grade 3 to 2 | 0 | 0 | 0 |
| AST increase — Grade 3 to 3 | 0 | 0 | 0 |
| AST increase — Grade 3 to 4 | 0 | 0 | 0 |
| AST increase — Grade 4 to 0 | 0 | 0 | 0 |
| AST increase — Grade 4 to 1 | 0 | 0 | 0 |
| AST increase — Grade 4 to 2 | 0 | 0 | 0 |
| AST increase — Grade 4 to 3 | 0 | 0 | 0 |
| AST increase — Grade 4 to 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 0 | 2 | 1 | 6 |
| Blood bilirubin increased — Grade 0 to 1 | 1 | 1 | 0 |
| Blood bilirubin increased — Grade 0 to 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 0 to 3 | 0 | 0 | 1 |
| Blood bilirubin increased — Grade 0 to 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 1 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 3 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 1 to 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 1 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 3 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 2 to 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 1 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 3 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 3 to 4 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 0 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 1 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 2 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 3 | 0 | 0 | 0 |
| Blood bilirubin increased — Grade 4 to 4 | 0 | 0 | 0 |
| CPK increased — Grade 0 to 0 | 3 | 2 | 5 |
| CPK increased — Grade 0 to 1 | 0 | 0 | 0 |
| CPK increased — Grade 0 to 2 | 0 | 0 | 0 |
| CPK increased — Grade 0 to 3 | 0 | 0 | 0 |
| CPK increased — Grade 0 to 4 | 0 | 0 | 0 |
| CPK increased — Grade 1 to 0 | 0 | 0 | 1 |
| CPK increased — Grade 1 to 1 | 0 | 0 | 0 |
| CPK increased — Grade 1 to 2 | 0 | 0 | 0 |
| CPK increased — Grade 1 to 3 | 0 | 0 | 0 |
| CPK increased — Grade 1 to 4 | 0 | 0 | 0 |
| CPK increased — Grade 2 to 0 | 0 | 0 | 0 |
| CPK increased — Grade 2 to 1 | 0 | 0 | 0 |
| CPK increased — Grade 2 to 2 | 0 | 0 | 0 |
| CPK increased — Grade 2 to 3 | 0 | 0 | 0 |
| CPK increased — Grade 2 to 4 | 0 | 0 | 0 |
| CPK increased — Grade 3 to 0 | 0 | 0 | 0 |
| CPK increased — Grade 3 to 1 | 0 | 0 | 0 |
| CPK increased — Grade 3 to 2 | 0 | 0 | 0 |
| CPK increased — Grade 3 to 3 | 0 | 0 | 0 |
| CPK increased — Grade 3 to 4 | 0 | 0 | 0 |
| CPK increased — Grade 4 to 0 | 0 | 0 | 0 |
| CPK increased — Grade 4 to 1 | 0 | 0 | 0 |
| CPK increased — Grade 4 to 2 | 0 | 0 | 0 |
| CPK increased — Grade 4 to 3 | 0 | 0 | 0 |
| CPK increased — Grade 4 to 4 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 0 | 1 | 2 | 5 |
| Chronic kidney disease — Grade 0 to 1 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 2 | 0 | 0 | 1 |
| Chronic kidney disease — Grade 0 to 3 | 1 | 0 | 0 |
| Chronic kidney disease — Grade 0 to 4 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 0 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 1 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 2 | 1 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 3 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 1 to 4 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 0 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 1 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 2 | 0 | 0 | 1 |
| Chronic kidney disease — Grade 2 to 3 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 2 to 4 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 0 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 1 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 2 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 3 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 3 to 4 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 0 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 1 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 2 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 3 | 0 | 0 | 0 |
| Chronic kidney disease — Grade 4 to 4 | 0 | 00 | 0 |
| Creatinine increased — Grade 0 to 0 | 1 | 2 | 5 |
| Creatinine increased — Grade 0 to 1 | 0 | 0 | 1 |
| Creatinine increased — Grade 0 to 2 | 0 | 0 | 0 |
| Creatinine increased — Grade 0 to 3 | 1 | 0 | 0 |
| Creatinine increased — Grade 0 to 4 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 1 | 1 | 0 | 1 |
| Creatinine increased — Grade 1 to 2 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 3 | 0 | 0 | 0 |
| Creatinine increased — Grade 1 to 4 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 1 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 2 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 3 | 0 | 0 | 0 |
| Creatinine increased — Grade 2 to 4 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 1 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 2 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 3 | 0 | 0 | 0 |
| Creatinine increased — Grade 3 to 4 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 0 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 1 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 2 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 3 | 0 | 0 | 0 |
| Creatinine increased — Grade 4 to 4 | 0 | 0 | 0 |
| Hypercalcemia — Grade 0 to 0 | 2 | 2 | 7 |
| Hypercalcemia — Grade 0 to 1 | 1 | 0 | 0 |
| Hypercalcemia — Grade 0 to 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 to 3 | 0 | 0 | 00 |
| Hypercalcemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 to 0 | 2 | 1 | 6 |
| Hyperkalemia — Grade 0 to 1 | 0 | 1 | 1 |
| Hyperkalemia — Grade 0 to 2 | 1 | 0 | 0 |
| Hyperkalemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hyperkalemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 0 | 3 | 2 | 6 |
| Hypermagnesemia — Grade 0 to 1 | 0 | 0 | 1 |
| Hypermagnesemia — Grade 0 to 2 | NA | NA | NA |
| Hypermagnesemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 2 | NA | NA | NA |
| Hypermagnesemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 2 to 0 | NA | NA | NA |
| Hypermagnesemia — Grade 2 to 1 | NA | NA | NA |
| Hypermagnesemia — Grade 2 to 2 | NA | NA | NA |
| Hypermagnesemia — Grade 2 to 3 | NA | NA | NA |
| Hypermagnesemia — Grade 2 to 4 | NA | NA | NA |
| Hypermagnesemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 2 | NA | NA | NA |
| Hypermagnesemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 2 | NA | NA | NA |
| Hypermagnesemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 to 0 | 3 | 2 | 6 |
| Hypernatremia — Grade 0 to 1 | 0 | 0 | 1 |
| Hypernatremia — Grade 0 to 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 to 0 | 1 | 2 | 4 |
| Hypoalbuminemia — Grade 0 to 1 | 1 | 0 | 1 |
| Hypoalbuminemia — Grade 0 to 2 | 1 | 0 | 2 |
| Hypoalbuminemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 0 to 4 | NA | NA | NA |
| Hypoalbuminemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 1 to 4 | NA | NA | NA |
| Hypoalbuminemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 2 to 4 | NA | NA | NA |
| Hypoalbuminemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypoalbuminemia — Grade 3 to 4 | NA | NA | NA |
| Hypoalbuminemia — Grade 4 to 0 | NA | NA | NA |
| Hypoalbuminemia — Grade 4 to 1 | NA | NA | NA |
| Hypoalbuminemia — Grade 4 to 2 | NA | NA | NA |
| Hypoalbuminemia — Grade 4 to 3 | NA | NA | NA |
| Hypoalbuminemia — Grade 4 to 4 | NA | NA | NA |
| Hypocalcemia — Grade 0 to 0 | 2 | 2 | 6 |
| Hypocalcemia — Grade 0 to 1 | 1 | 0 | 0 |
| Hypocalcemia — Grade 0 to 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 1 | 0 | 0 | 1 |
| Hypocalcemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 to 0 | 3 | 2 | 7 |
| Hypoglycemia — Grade 0 to 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 to 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypokalemia — Grade 0 to 0 | 2 | 1 | 4 |
| Hypokalemia — Grade 0 to 1 | NA | NA | NA |
| Hypokalemia — Grade 0 to 2 | 0 | 1 | 2 |
| Hypokalemia — Grade 0 to 3 | 1 | 0 | 0 |
| Hypokalemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypokalemia — Grade 1 to 0 | NA | NA | NA |
| Hypokalemia — Grade 1 to 1 | NA | NA | NA |
| Hypokalemia — Grade 1 to 2 | NA | NA | NA |
| Hypokalemia — Grade 1 to 3 | NA | NA | NA |
| Hypokalemia — Grade 1 to 4 | NA | NA | NA |
| Hypokalemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 to 1 | NA | NA | NA |
| Hypokalemia — Grade 2 to 2 | 0 | 0 | 1 |
| Hypokalemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypokalemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 1 | NA | NA | NA |
| Hypokalemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 1 | NA | NA | NA |
| Hypokalemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypokalemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 0 | 2 | 2 | 3 |
| Hypomagnesemia — Grade 0 to 1 | 0 | 0 | 4 |
| Hypomagnesemia — Grade 0 to 2 | 1 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 0 to 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 1 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 1 to 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 1 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 2 to 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 1 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 to 4 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 0 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 1 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 to 4 | 0 | 0 | 0 |
| Hyponatremia — Grade 0 to 0 | 2 | 1 | 4 |
| Hyponatremia — Grade 0 to 1 | 1 | 0 | 0 |
| Hyponatremia — Grade 0 to 2 | NA | NA | NA |
| Hyponatremia — Grade 0 to 3 | 0 | 0 | 3 |
| Hyponatremia — Grade 0 to 4 | 0 | 0 | 0 |
| Hyponatremia — Grade 1 to 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 1 to 1 | 0 | 0 | 0 |
| Hyponatremia — Grade 1 to 2 | NA | NA | NA |
| Hyponatremia — Grade 1 to 3 | 0 | 1 | 0 |
| Hyponatremia — Grade 1 to 4 | 0 | 0 | 0 |
| Hyponatremia — Grade 2 to 0 | NA | NA | NA |
| Hyponatremia — Grade 2 to 1 | NA | NA | NA |
| Hyponatremia — Grade 2 to 2 | NA | NA | NA |
| Hyponatremia — Grade 2 to 3 | NA | NA | NA |
| Hyponatremia — Grade 2 to 4 | NA | NA | NA |
| Hyponatremia — Grade 3 to 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 to 1 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 to 2 | NA | NA | NA |
| Hyponatremia — Grade 3 to 3 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 to 4 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 0 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 1 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 2 | NA | NA | NA |
| Hyponatremia — Grade 4 to 3 | 0 | 0 | 0 |
| Hyponatremia — Grade 4 to 4 | 0 | 0 | 0 |
| Lipase increased — Grade 0 to 0 | 1 | 2 | 5 |
| Lipase increased — Grade 0 to 1 | 2 | 0 | 0 |
| Lipase increased — Grade 0 to 2 | 0 | 0 | 1 |
| Lipase increased — Grade 0 to 3 | 0 | 0 | 1 |
| Lipase increased — Grade 0 to 4 | 0 | 0 | 0 |
| Lipase increased — Grade 1 to 0 | 0 | 0 | 0 |
| Lipase increased — Grade 1 to 1 | 0 | 0 | 0 |
| Lipase increased — Grade 1 to 2 | 0 | 0 | 0 |
| Lipase increased — Grade 1 to 3 | 0 | 0 | 0 |
| Lipase increased — Grade 1 to 4 | 0 | 0 | 0 |
| Lipase increased — Grade 2 to 0 | 0 | 0 | 0 |
| Lipase increased — Grade 2 to 1 | 0 | 0 | 0 |
| Lipase increased — Grade 2 to 2 | 0 | 0 | 0 |
| Lipase increased — Grade 2 to 3 | 0 | 0 | 0 |
| Lipase increased — Grade 2 to 4 | 0 | 0 | 0 |
| Lipase increased — Grade 3 to 0 | 0 | 0 | 0 |
| Lipase increased — Grade 3 to 1 | 0 | 0 | 0 |
| Lipase increased — Grade 3 to 2 | 0 | 0 | 0 |
| Lipase increased — Grade 3 to 3 | 0 | 0 | 0 |
| Lipase increased — Grade 3 to 4 | 0 | 0 | 0 |
| Lipase increased — Grade 4 to 0 | 0 | 0 | 0 |
| Lipase increased — Grade 4 to 1 | 0 | 0 | 0 |
| Lipase increased — Grade 4 to 2 | 0 | 0 | 0 |
| Lipase increased — Grade 4 to 3 | 0 | 0 | 0 |
| Lipase increased — Grade 4 to 4 | 0 | 0 | 0 |
| Serum amylase increased — Grade 0 to 0 | 2 | 2 | 4 |
| Serum amylase increased — Grade 0 to 1 | 1 | 0 | 1 |
| Serum amylase increased — Grade 0 to 2 | 0 | 0 | 0 |
| Serum amylase increased — Grade 0 to 3 | 0 | 0 | 0 |
| Serum amylase increased — Grade 0 to 4 | 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 0 | 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 1 | 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 2 | 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 3 | 0 | 0 | 0 |
| Serum amylase increased — Grade 1 to 4 | 0 | 0 | 0 |
| Serum amylase increased — Grade 2 to 0 | 0 | 0 | 0 |
| Serum amylase increased — Grade 2 to 1 | 0 | 0 | 0 |
| Serum amylase increased — Grade 2 to 2 | 0 | 0 | 1 |
| Serum amylase increased — Grade 2 to 3 | 0 | 0 | 1 |
| Serum amylase increased — Grade 2 to 4 | 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 0 | 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 1 | 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 2 | 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 3 | 0 | 0 | 0 |
| Serum amylase increased — Grade 3 to 4 | 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 0 | 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 1 | 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 2 | 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 3 | 0 | 0 | 0 |
| Serum amylase increased — Grade 4 to 4 | 0 | 0 | 0 |
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Phase 1b of Sub-Study B: Objective Response Rate | 0.0 (0.0 to 70.8) | 0.0 (0.0 to 45.9) |
DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
No measurements were reported for this outcome.
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
No measurements were reported for this outcome.
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
| Months | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Phase 1b of Sub-Study B: Progression-Free Survival (PFS) | 3.6 (0.7 to NA) | 6.5 (3.6 to NA) |
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
| Months | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 of Sub-Study B: Duration of Response (DR) | NA (NA to NA) | NA (NA to NA) | 5.8 (NA to NA) |
TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
| Months | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 of Sub-Study B: Time to Tumor Response (TTR) | 4.1 (4.1 to 4.1) | 1.3 (1.3 to 1.3) | 1.4 (1.4 to 1.4) |
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
| Months | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 of Sub-Study B: Progression-Free Survival (PFS) | 4.2 (4.0 to NA) | NA (2.8 to NA) | 3.4 (1.4 to NA) |
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
| Months | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 of Sub-Study B: Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | 4.0 (NA to NA) |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Cycle 1 | 8840 ± 127 | 11570 ± 79 |
| Cycle 5 | 23080 ± NA | 47340 ± 42 |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Cycle 1 Day 1 | 5.094 ± NA | 22.81 ± 80 |
| Cycle 1 Day 8 | 3.440 ± NA | 13.74 ± 106 |
| Cycle 5 Day 1 | — | 33.79 ± 73 |
| Cycle 5 Day 8 | 13.10 ± NA | 24.85 ± NA |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|
| Cycle 1 | 42550 ± 109 |
| Cycle 5 | 32660 ± 17 |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 | 11780 ± 45 | 13810 ± NA | 10350 ± 45 |
| Cycle 5 | — | 43500 ± NA | 20600 ± NA |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 Day 1 | 37.43 ± 85 | 18.23 ± NA | 11.18 ± 112 |
| Cycle 1 Day 8 | 39.50 ± NA | 2.360 ± NA | 2.708 ± 132 |
| Cycle 5 Day 1 | — | 11.10 ± NA | 7.710 ± NA |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 | 36970 ± 36 | 35500 ± NA | 30590 ± 39 |
| Cycle 5 | — | 43000 ± NA | 44900 ± NA |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Cycle 5 | 23000 ± NA | 23170 ± 29 |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| Cycle 1 Day 8 | 3.440 ± NA | 13.74 ± 106 |
| Cycle 5 Day 1 | — | 29.42 ± NA |
| Cycle 5 Day 8 | 13.10 ± NA | 24.85 ± NA |
| Nanograms per milliliter | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|
| Cycle 5 | 4813 ± 35 |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 | — | — | 87.01 ± NA |
| Cycle 5 | — | 30400 ± NA | 20000 ± NA |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 Day 8 | 39.50 ± NA | 2.360 ± NA | 2.708 ± 132 |
| Cycle 5 Day 1 | — | — | 3.630 ± NA |
| Nanograms per milliliter | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Cycle 1 | — | 55.00 ± NA | 24.47 ± NA |
| Cycle 5 | — | 5770 ± NA | 8490 ± NA |
A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
| Participants | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) |
|---|---|---|
| ADA against sasanlimab | 0 | 1 |
| ADA against SEA-TGT | — | 0 |
| Participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| ADA against sasanlimab | 0 | 0 | 0 |
| ADA against SEA-TGT | 1 | 0 | 0 |
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
| Percentage of participants | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|
| Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue | 33.3 (0.8 to 90.6) | 0 (0.0 to 84.2) | 14.3 (0.4 to 57.9) |
Collected over From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | 4/9 (44.4%) | 7/9 (77.8%) | 9/9 (100%) |
| Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | 5/6 (83.3%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | 3/7 (42.9%) | 4/7 (57.1%) | 7/7 (100%) |
| Event | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| EnteritisGastrointestinal disorders | 0/4 | 0/9 | 0/3 | 0/6 | 1/3 | 0/2 | 0/7 |
| ColitisGastrointestinal disorders | 0/4 | 0/9 | 0/3 | 0/6 | 1/3 | 0/2 | 0/7 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/4 | 0/9 | 1/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 0/4 | 0/9 | 0/3 | 0/6 | 1/3 | 0/2 | 0/7 |
| DiverticulitisInfections and infestations | 1/4 | 0/9 | 0/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| Lower respiratory tract infectionInfections and infestations | 1/4 | 0/9 | 0/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| PneumoniaInfections and infestations | 1/4 | 0/9 | 0/3 | 1/6 | 0/3 | 0/2 | 1/7 |
| Supraventricular tachycardiaCardiac disorders | 1/4 | 0/9 | 0/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| Ejection fraction decreasedInvestigations | 1/4 | 0/9 | 0/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| PyrexiaGeneral disorders | 0/4 | 2/9 | 0/3 | 0/6 | 0/3 | 0/2 | 0/7 |
| Event | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) |
|---|---|---|---|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 1/4 | 3/9 | 3/3 | 1/6 | 1/3 | 1/2 | 2/7 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/4 | 0/9 | 0/3 | 1/6 | 0/3 | 2/2 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 3/9 | 2/3 | 2/6 | 2/3 | 0/2 | 0/7 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/9 | 2/3 | 0/6 | 1/3 | 0/2 | 1/7 |
| ConstipationGastrointestinal disorders | 2/4 | 2/9 | 0/3 | 2/6 | 2/3 | 0/2 | 2/7 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 3/9 | 1/3 | 3/6 | 2/3 | 0/2 | 3/7 |
| NauseaGastrointestinal disorders | 2/4 | 3/9 | 0/3 | 1/6 | 2/3 | 0/2 | 3/7 |
| FatigueGeneral disorders | 1/4 | 4/9 | 2/3 | 3/6 | 2/3 | 1/2 | 3/7 |
| Alanine aminotransferase increasedInvestigations | 1/4 | 4/9 | 2/3 | 1/6 | 1/3 | 1/2 | 2/7 |
| Blood alkaline phosphatase increasedInvestigations | 1/4 | 1/9 | 1/3 | 1/6 | 2/3 | 1/2 | 0/7 |
Full analysis set included all participants who received at least 1 dose of study drug. Participants were classified according to the treatment actually received.
| Age, Categorical(Participants) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 5 | 0 | 1 | 1 | 0 | 5 | 13 |
| >=65 years | 3 | 4 | 3 | 5 | 2 | 2 | 2 | 21 |
| Sex: Female, Male(Participants) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 1 | 1 | 1 | 1 | 2 | 12 |
| Male | 1 | 6 | 2 | 5 | 2 | 1 | 5 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Not Hispanic or Latino | 4 | 8 | 3 | 6 | 3 | 2 | 6 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 5 | 0 | 1 | 0 | 0 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 4 |
| White | 2 | 4 | 3 | 3 | 2 | 2 | 7 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2020 to primary completion in May 2023, 30 months.
Results were first posted in Jun 2023, 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Encorafenib · Binimetinib · Sasanlimab
Carcinoma, Non-Small-Cell Lung →